Modified lantibiotics and methods of making and using the modified lantibiotics

ABSTRACT

The subject invention pertains to a modified lantibiotic containing an intact cysteine at the C-terminus, particularly, a cysteine that is not decarboxylated and that contains a free carboxyl group. Derivatives of the modified lantibiotic comprising a moiety conjugated to the carboxyl group of the terminal cysteine are also provided. A bacterium that produces a modified lantibiotic having an intact cysteine at the C-terminus are also provided, wherein the bacterium is genetically modified to inactivate a gene that encodes a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic. Methods of producing a modified lantibiotic having an intact cysteine at the C-terminus by culturing a bacterium that synthesizes the modified lantibiotic and purifying the lantibiotic are also provided. Mutants of lantibiotics, particularly, mutacin 1140 having higher anti-bacterial activity or higher bacterial expression compared to mutacin 1140 are also provided.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. application Ser. No. 15/797,001, filed Oct. 30, 2017, now U.S. Pat. No. 10,577,399, which claims the benefit of U.S. Provisional Application Ser. No. 62/414,334, filed Oct. 28, 2016, the disclosures of which are hereby incorporated by reference in their entirety, including all figures, tables and amino acid or nucleic acid sequences.

The Sequence Listing for this application is labeled “Seq-List.txt” which was created on Oct. 2, 2019 and is 25 KB. The entire content of the sequence listing is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Lantibiotics are characterized by their post-translational modifications (PTMs). Dehydrations of serine and threonine residues into dehydroalanine and dehydrobutyrine residues, respectively, are common modifications found in lantibiotics. These dehydrated residues are cyclized with cysteines to form thioether bridges, which are called lanthionines¹⁻². Lantibiotics can contain other post-translational modifications, such as D-alanines in lacticin 3147, β-hydroxy aspartate in cinnamycin, 2-oxopropionyl in lactocin S, and an oxidized lanthionine in actagardine³⁻⁶.

The epidermin group of lantibiotics and other lantibiotic peptides have a S—[(Z)-2-aminovinyl]-D-cysteine (AviCys) residue at the C-terminal end of the peptide (FIG. 1a ). This residue consists of a decarboxylated cysteine which forms a lanthionine ring. Several of these modifications are important for lantibiotic activity; however, the importance of the AviCys for the lantibiotic activity in the epidermin group of lantibiotics is not known.

Mutacin 1140, produced by Streptococcus mutans JH1140, is a lantibiotic that has shown promise as a potential therapeutic (FIG. 1b )⁷⁻⁹. It has a broad spectrum of activity against Gram-positive bacteria¹⁰. Further, mutacin 1140 has been shown to clear Staphylococcus aureus infections in rodent models with little toxicity¹¹. The bacterium producing mutacin 1140 has been engineered into a therapy for preventing dental caries¹².

Mutacin 1140 belongs to the class I epidermin group of lantibiotics and is structurally related to epidermin and gallidermin¹³⁻¹⁴. The first two lanthionine rings, rings A and B, of the epidermin group are referred to as the lipid II binding domain. The lantibiotic nisin shares structural homology to the lanthionine rings A&B. The latter half of the epidermin and nisin peptide is referred to as the lateral assembly domain, which presumably abducts lipid II into large lipid II/lantibiotic complexes¹⁵⁻¹⁶.

Decarboxylation of a C-terminal cysteine to form an AviCys residue occurs in several metabolites¹⁷. AviCys is present in the class II lantibiotics mersacidin and microbisporicin¹⁷⁻¹⁸. It is also found in non-lantibiotics, such as cypemycin. Cypemycin contains many of the lantibiotic PTM modifications; however, it does not form lanthionine rings¹⁹. The AviCys residue has also been found in the nonribosomal peptide synthetases (NRPS) produced metabolite thiovideramide. The mechanism of AviCys formation for the NRPS peptide maybe different due the nature of its biosynthesis²⁰.

In certain lantibiotics, decarboxylation of cysteine at the C-terminus is performed by the flavoprotein LanD. This decarboxylase has been shown to be specific for C-terminal cysteines. Furthermore, LanD could not decarboxylate an ethyl-thioether mimic, suggesting decarboxylation occurs before ring D formation²¹. Crystal structures for both EpiD, the decarboxylase for epidermin, and MrsD, the decarboxylase for mersacidin, indicate that these enzymes form a homo-dodecamer²²⁻²³. Studies on the mechanism of activity suggest that decarboxylation produces an ene-thiol intermediate that promotes terminal ring formation²⁴. There have been no reports of an isolated carboxylated analog of an AviCys containing lantibiotic, even in an EpiD deletion mutant of epidermin biosynthesis²⁵.

HOAt/EDC coupling has been achieved for lantibiotics that contain a C-terminal carboxyl group. NVB302, an analog of actagardine which has undergone phase 1 clinical trials, has a diaminoheptane tail attached to the C-terminus of the lantibiotic²⁷. Additionally, lantibiotics can be produced through solid-phase peptide synthesis using orthogonally protected lanthionine rings²⁶⁻²⁸.

BRIEF SUMMARY OF THE INVENTION

Chemical modification of lantibiotics offers a novel avenue for the development of new therapeutics²⁶. The lack of a C-terminal carboxyl group complicates the further development of the lantibiotics containing a C-terminal cysteine, for example, epidermin group of lantibiotics, using C-terminal modifications. A free carboxyl group analog of the lantibiotics containing a C-terminal cysteine would promote studies aimed at understanding the functional basis for AviCys residues within the lantibiotic and promote the synthesis of lantibiotics having improved therapeutic efficacy.

Accordingly, an embodiment of the invention provides a modified lantibiotic containing an intact cysteine at the C-terminus, particularly, a cysteine that is not decarboxylated and that contains a free carboxyl group. Derivatives of the modified lantibiotic comprising a moiety conjugated to the carboxyl group of the terminal cysteine are also provided. In certain embodiments, the moiety conjugated to the carboxyl group of the modified lantibiotic having an intact C-terminal cysteine is a functional group or a detectable label.

A bacterium that produces a modified lantibiotic having an intact cysteine at the C-terminus is also provided, wherein the bacterium is genetically modified to inactivate a gene that encodes a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic.

Methods of producing a modified lantibiotic having an intact cysteine at the C-terminus by culturing a bacterium that synthesizes the modified lantibiotic and purifying the lantibiotic are also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication, with color drawing(s), will be provided by the Office upon request and payment of the necessary fee.

FIGS. 1A-1B. Structures of class I and class II lantibiotics. (A) Structures of class I lantibiotics: mutacin 1140 (SEQ ID NO: 33), epidermin (SEQ ID NO: 34), and nisin (SEQ ID NO: 35). Dehydrated residues are either Dha or Dhb. The lipid II binding domain of class I lantibiotics consist of the first two lanthionine rings A and B, while the lateral assembly domain consist of the terminal rings. (B) Structure of the class II lantibiotic, mersacidin (SEQ ID NO: 36), which contains an AviCys. Residues involved in AviCys formation are labeled in red for both classes.

FIG. 2. Scheme for chemical modification of mutacin 1140-COOH. Mu1140 COOH analog was coupled to various primary amines using HOAt/EDC coupling. Primary amines were chosen based on size and differences in physiochemical properties. Reaction conditions were constant for each substrate, and yields were greater than 80% for each substrate.

FIGS. 3A-3C. In vivo localization of mutacin 1140. B. subtilis PY79 cells were incubated with various fluorescein conjugated lantibiotics. (A) A no antibiotic sample was used as negative control. (B) Fluorescein conjugated nisin binds and abducts lipid II to form patches as expected. (C) Fluorescein conjugated mutacin 1140 has a similar localization pattern as nisin. Images were taken using a confocal Olympus microscope using a 100× objective, or a 40× objective for the control.

FIGS. 4A-4D. Lipid II competition assay of nisin and mu1140-COOH analog. B. subtilis cells were treated with mu1140-COOH to compete with nisin in binding to lipid II. (A) Solvent blank (no antibiotic) control. (B) Fluorescein labeled nisin binds tightly to lipid II to form patches. (C) Prior treatment of cells with mu1140 prevents binding of fluorescein labeled nisin. (D) Prior treatment of cells with mu1140-COOH drastically reduces binding of fluorescein labeled nisin. Images were taken using a confocal Olympus microscope using a 100× objective, or a 40× objective for the control.

FIGS. 5A-5C. Deletion of mutD in S. mutans JH1140. (A) Scheme for the deletion of mutD by IFDC2 gene replacement. (B) Deferred antagonism assay against M. luteus ATCC 10240 shows no zone of inhibition for either S. mutans IFDC2:mutD or S. mutans ΔmutD. S. mutans JH1140 and S. mutans ΔmutA were used as a positive and negative controls, respectively. (C) Purification of S. mutans IFDC2:mutD extracts (green) show a single peak, while there was no observable peak for S. mutans ΔmutA and ΔmutD.

FIGS. 6A-6B. Edman sequencing of mutacin 1140-COOH. (A) After double labeling with sodium borohydride and ethanethiol, a thio-ethyl cysteine (S-EC) or beta-methyl thio-ethyl cysteine (BM-S-EC) is expected at sites of lanthionine ring formation in the Edman sequence compared to mutacin 1140 (SEQ ID NO: 37). Blue circles indicate residues expected to form lanthionine rings, and green circles indicate sites of dehydration. (B) Select Edman sequence (SEQ ID NO: 38) spectras for the modified residues indicate full modification of mu1140-COOH. The red X or black circles indicate residues with no signal acquired.

FIG. 7. In vitro lipid II binding assay. TLC plate assay of mutacin 1140 or mu1140-COOH mixed with lipid II. Binding of lipid II will keep lipid II at the origin. Lipid II or mu1140-COOH by itself was used as a negative control showing no staining. Lipid II and mutacin 1140 was used as a positive control for trapping lipid II at the origin.

FIG. 8. Overlay assay comparing the zone of inhibitions for select mutations within the core peptide of mutacin 1140. The bioactivity is compared to the relative activity (zone of Inhibition) of the wild-type strain. The deletion strain of mutA is used as a negative control.

FIGS. 9-10. Mature forms of certain lantibiotics. Mutacin B-Ny266 (SEQ ID NO: 39); Mutacin 1140 (SEQ ID NO: 33); Microbisporicin (SEQ ID NO: 40); Mutacin I (SEQ ID NO: 41); Epidermin (SEQ ID NO: 34); Gallidermin (SEQ ID NO: 42); Mersacidin (SEQ ID NO: 43); Lichenicidin A2 (SEQ ID NO: 44); Lactocin S (SEQ ID NO: 45); Mutacin II (SEQ ID NO: 46); Epidermin (SEQ ID NO: 34); Gallidermin (SEQ ID NO: 42); Salivaricin (SEQ ID NO: 47); Lacticin 3147-A2 (SEQ ID NO: 48); Actagardine (SEQ ID NO: 49); Mersacidin (SEQ ID NO: 43); Mutacin B-hy266 (SEQ ID NO: 39); Mutacin 1140 (SEQ ID NO: 33); Ruminococcin A (SEQ ID NO: 50); and Microbisporicin (SEQ ID NO: 40).

FIG. 11. Bioactivity of core peptide mutants compared to wild-type S. mutans. The bioactivity is represented as the ratio of the zone of inhibition of mutant to wild-type strain. * denotes statistical significance.

FIGS. 12A-12B. Pharmacokinetic and pharmacodynamic analysis of mutacin 1140 and mutacin 1140 core peptide mutants. A. Plasma concentrations of native mutacin 1140 (blue), R13A (orange), S5G (yellow), and S5A:T14G (grey) following an intravenous administration of a 2.5 mg/Kg dose. B. Kill kinetics of wild-type mutacin 1140 (blue; at 0.5 μg/ml) and R13A (orange; at 0.125 μg/ml) against S. pneumoniae ATCC 27336.

FIG. 13. Typsin stability of mutacin 1140 core peptide mutants. WT denotes wild-type mutacin 1140. Overlay assay was done using M. luteus as an indicator strain.

BRIEF DESCRIPTION OF THE SEQUENCES

SEQ ID NO: 1-13: Sequences of exemplary lantibiotic propeptides.

SEQ ID NO: 14-26: Sequences of exemplary mature lantibiotics.

SEQ ID NO: 27: Forward primer for mutD replacement.

SEQ ID NO: 28: Reverse primer for mutD replacement.

SEQ ID NO: 29: Forward primer for mutD replacement.

SEQ ID NO: 30: Reverse primer for mutD replacement.

SEQ ID NO: 31: Forward primer for mutD clean deletion.

SEQ ID NO: 32: Reverse primer for mutD clean deletion.

DETAILED DISCLOSURE OF THE INVENTION

As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Further, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising”. The transitional terms/phrases (and any grammatical variations thereof) “comprising”, “comprises”, “comprise”, include the phrases “consisting essentially of”, “consists essentially of”, “consisting”, and “consists”.

The phrases “consisting essentially of” or “consists essentially of” indicate that the claim encompasses embodiments containing the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claim.

“Pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the modified lantibiotics described herein, its use in the pharmaceutical compositions of the invention is contemplated.

“Treatment”, “treating”, “palliating” and “ameliorating” (and grammatical variants of these terms), as used herein, are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit. A therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder, for example, a bacterial infection.

The term “effective amount” or “therapeutically effective amount” refers to that amount of an inhibitor described herein that is sufficient to effect the intended application including but not limited to disease treatment, for example, clearing a bacterial infection. The therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The specific dose will vary depending on the particular lantibiotic chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.

“Subject” refers to an animal, such as a mammal, for example a human. The methods described herein can be useful in both humans and non-human animals. In some embodiments, the subject is a mammal.

As used herein, “a lantibiotic” is a protein produced by a bacterium that is active against another bacterium and that contains one or more thioether bridges called lanthionines. A lantibiotics contains one or more amino acids having PTMs, for example, dehydrations of serine and threonine residues into dehydroalanine and dehydrobutyrine residues, respectively. In addition, these dehydrated residues are cyclized with cysteines to form thioether bridges called lanthionines.

The epidermin group of lantibiotics and certain other lantibiotics have S—[(Z)-2-aminovinyl]-D-cysteine (AviCys) residue at the C-terminal end of the lantibiotic (FIG. 1a ). This residue is produced by decarboxylation of the cysteine at the C-terminus of precursor lantibiotic peptide. AviCys forms a lanthionine ring with other post-translationally modified amino acids of the lantibiotic peptide.

As used herein, “a lantibiotic peptide” refers to a peptide that does not contain any PTMs. Post-translational modification of the lantibiotic peptide produces a lantibiotic.

As used herein, a “precursor lantibiotic” refers to a peptide that contains an intact cysteine at the C-terminus of the lantibiotic, i.e., a cysteine at the C-terminus of the precursor lantibiotic that is not decarboxylated and that contains a free carboxyl group. A “precursor lantibiotic” may or may not contain the other PTMs present in the corresponding lantibiotic.

The term “modified lantibiotic” refers to a lantibiotic that contains all the other PTMs present in a lantibiotic, except the PTMs to the cysteine at the C-terminus of the lantibiotic. Accordingly, in a modified lantibiotic, the cysteine at the C-terminus is not decarboxylated and contains a free carboxyl group and the modified lantibiotic contains all the other PTMs present in the corresponding lantibiotic.

The term “parent lantibiotic” is used herein to distinguish a “modified lantibiotic” or a “functionalized lantibiotic” from the corresponding “lantibiotic”. For example, a “modified mutacin” contains all the other PTMs present in mutacin, except the PTMs to the cysteine at the C-terminus of mutacin. Similarly, a “functionalized mutacin” contains all the other PTMs present in mutacin, except the PTMs to the cysteine at the C-terminus of mutacin and wherein the carboxyl group of the cysteine at the C-terminus is conjugated to a moiety.

A “native gene” or “an endogenous gene” is a gene that is naturally found in a bacterium; whereas, an “exogenous gene” is a gene introduced into a bacterium and which was obtained from an organism other the bacterium.

The invention relates to the importance of the C-terminal S—[(Z)-2-aminovinyl]-D-cysteine (AviCys) residue for antibacterial activity of lantibiotics. The PTM for making the AviCys residue is essential for the lateral assembly mechanism of activity that traps lipid II into a large complex.

Accordingly, one embodiment of the invention provides a modified lantibiotic having an intact cysteine at the C-terminus. Non-limiting examples of parent lantibiotics that correspond to the modified lantibiotics described herein include lichenicidin (e.g., SEQ ID NO: 1), lactocin-S (e.g., SEQ ID NO: 2), salivaricin (e.g., SEQ ID NO: 3), mutacin (e.g., SEQ ID NOs: 4, 10 and 11), lacticin (e.g., SEQ ID NO: 5), actagardine (e.g., SEQ ID NO: 6), mersacidin (e.g., SEQ ID NO: 7), epidermin (e.g., SEQ ID NO: 8), gallidermin (e.g., SEQ ID NO: 9), ruminococcin (e.g., SEQ ID NO: 12) or microbisporicin (SEQ ID NO: 13).

The modified lantibiotics having an intact cysteine at the C-terminus can be further conjugated to moieties through the free carboxyl group of the cysteine at the C-terminus. Accordingly, functionalized lantibiotic is provided, wherein the carboxyl group of the cysteine at the C-terminus is conjugated to a moiety.

The moiety can be a functional group or a detectable label. Non-limiting examples of the functional groups that can be conjugated to the carboxyl group of the cysteine at the C-terminus of the modified lantibiotic include substituted or unsubstituted chemical groups, such as alkane, alkene, alkyne, haloalkyl, alcohol, ether, amine, aldehyde, ketone, acyl halide, carboxylate, ester, amide, aryl or heteroaryl. Specific embodiments within the genus of chemical groups recited herein are well known in the art and such embodiments are within the purview of the invention.

The carboxyl group of the cysteine at the C-terminus of the modified lantibiotic can be covalently joined to a carbon or a heteroatom of the functional group.

In one embodiment, the carboxyl group of the cysteine at the C-terminus of the modified lantibiotic is covalently joined to a carbon or the nitrogen atom of an amine. The amine can be a primary or secondary amine. Non-limiting examples of amines include substituted or unsubstituted forms of alkyl-amines, for example, methylamine or diaminoheptane, or substituted or unsubstituted forms of aryl-amines or heteroaryl amines, for example, chlorophenylalanine or di-chlorophenylalanine.

In specific embodiments, the functional group is substituted halo-aryl, for example, chlorophenylalanine or di-chlorophenylalanine.

In another embodiment of the functionalized lantibiotic, the moiety is a detectable label. The detectable label can be a fluorescent label, radiolabel or bioluminescent label.

Numerous commercially available fluorescent labels are suitable for conjugation to the modified lantibiotic described herein, for example, fluorescein, dR110, 5-FAM™ 6-FAM™, dR6G, JOE™, HEX™, VIC®, TET™, dTAMRA™, TAMRA™, NED™, dROX™, ROX™, PET® and LIZ®. Additional examples of fluorescent labels suitable for the invention described herein are known to a skilled artisan and such embodiments are within the purview of the invention.

Non-limiting examples of parent lantibiotics that correspond to the functionalized lantibiotics described herein include lichenicidin (e.g., SEQ ID NO: 1), lactocin-S (e.g., SEQ ID NO: 2), salivaricin (e.g., SEQ ID NO: 3), mutacin (e.g., SEQ ID NOs: 4, 10 (mutacin ny266) and 11 (mutacin 1140/mutacin III)), lacticin (e.g., SEQ ID NO: 5), actagardine (e.g., SEQ ID NO: 6), mersacidin (e.g., SEQ ID NO: 7), epidermin (e.g., SEQ ID NO: 8), gallidermin (e.g., SEQ ID NO: 9), ruminococcin (e.g., SEQ ID NO: 12) or microbisporicin (SEQ ID NO: 13).

In certain embodiments, a parent lantibiotic that corresponds to the functionalized lantibiotics described herein comprises a sequence that is homologous to the sequence of a known lantibiotic, for example, lichenicidin (e.g., SEQ ID NO: 1), lactocin-S (e.g., SEQ ID NO: 2), salivaricin (e.g., SEQ ID NO: 3), mutacin (e.g., SEQ ID NOs: 4, 10 and 11), lacticin (e.g., SEQ ID NO: 5), actagardine (e.g., SEQ ID NO: 6), mersacidin (e.g., SEQ ID NO: 7), epidermin (e.g., SEQ ID NO: 8), gallidermin (e.g., SEQ ID NO: 9), ruminococcin (e.g., SEQ ID NO: 12) or microbisporicin (SEQ ID NO: 13). A lantibiotic that is homologous to known lantibiotic shares at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the sequences of the corresponding known lantibiotic, for example, lichenicidin (e.g., SEQ ID NO: 1), lactocin-S (e.g., SEQ ID NO: 2), salivaricin (e.g., SEQ ID NO: 3), mutacin (e.g., SEQ ID NOs: 4, 10 and 11), lacticin (e.g., SEQ ID NO: 5), actagardine (e.g., SEQ ID NO: 6), mersacidin (e.g., SEQ ID NO: 7), epidermin (e.g., SEQ ID NO: 8), gallidermin (e.g., SEQ ID NO: 9), ruminococcin (e.g., SEQ ID NO: 12) or microbisporicin (SEQ ID NO: 13).

For the purpose of this invention, when a sequence of lantibiotic is represented by a sequence identifier, the sequence in the sequence identifier provides the amino acids sequence of the lantibiotic prior to any PTMs. The amino acids provided in a sequence that corresponds to a lantibiotic are post-translationally modified to produce a lantibiotic having antibacterial activity. Such PTMs include, for example, dehydrations of serine and threonine residues into dehydroalanine and dehydrobutyrine residues, respectively; cyclization of the dehydrated residues with cysteines to form thioether bridges called lanthionines; formation of D-alanines (e.g., in lacticin 3147); formation of β-hydroxy aspartate (e.g., in cinnamycin); formation of 2-oxopropionyl (e.g., in lactocin S); and oxidation of lanthionine (e.g., in actagardine); formation of AviCys at the C-terminal end of the peptide (e.g., in mutacin).

A person of ordinary skill in the art can design homologs of a given lantibiotic by substituting the amino acids within a lantibiotic sequence that are not likely to affect the activity of the lantibiotic having an amino acid substitution. For example, a person of ordinary skill in the art can substitute amino acids that are not modified via PTMs in a lantibiotic, particularly, with other amino acids that have similar chemical properties via conservative amino acid substitutions.

Conservative amino acid substitutions are changes in a protein sequence that change an amino acid to a different amino acid with similar biochemical properties, e.g. charge, hydrophobicity and size. Certain examples of conservative substitutions are provided in Table 1 below:

TABLE 1 Conservative amino acid substitutions to produce homologs of a lantibiotic Original residue Substitution Ala (A) Val (V), Leu (L), Ile (I) Arg (R) Lys (K), Gln (Q), Asn (N) Asn (N) Gln (Q), His (H), Lys (K), Arg (R) Asp (D) Glu (E) Cys (C) Ser (S) Gln (Q) Asn (N) Glu (E) Asp (D) His (H) Asn (N), Gln (Q), Lys (K), Arg (R) Ile (I) Leu (L), Val (V), Met (M), Ala (A), Phe (F) Leu (L) Ile (I), Val (V), Met (M), Ala (A), Phe (F) Lys (K) Arg (R), Gln (Q), Asn (N) Met (M) Leu (L), Phe (F), Ile (I) Phe (F) Leu (L), Val (V), Ile (I), Ala (A) Pro (P) Gly (G) Ser (S) Thr (T) Thr (T) Ser (S) Trp (W) Tyr (Y) Tyr (Y) Trp (W), Phe (F), Thr (T), Ser (S) Val (V) Ile (I), Leu (L), Met (M), Phe (F), Ala (A).

In certain embodiments, the invention provides mutant lantibiotics having one or more mutations in the core peptide. Such mutants are called core peptide mutants. Certain of the core peptide mutants of the invention exhibit higher activity, improved pharmacokinetics, higher stability, or a combination thereof, compared to the corresponding unmodified lantibiotic.

In specific embodiments, the invention provides core peptide mutants of mutacin, particularly, mutacin 1140 comprising the sequence of SEQ ID NO: 24 or mutacin B-Ny266 comprising the sequence of SEQ ID NO: 23. In other embodiments, a core peptide mutant of mutacin 1140 or mutacin B-Ny266 comprises or consists of a mutation provided in the Table 2 below.

TABLE 2 Examples of core peptide mutants of mutacin 1140 comprising SEQ ID NO: 24 or mutacin B-Ny266 comprising the sequence of SEQ ID NO: 23 containing a single amino acid mutation/substitution. For mutacin 1140, the amino acid positions are indicated with respect to SEQ ID NO: 24 and for mutacin B-Ny266, the amino acid positions are indicated with respect to SEQ ID NO: 23. Mutations in the corresponding positions of mutacin 1140 or mutacin B-Ny266 prior to post-translational modification comprising SEQ ID NO: 10 or 11, respectively, are also envisioned. Amino acid Original Replacement position amino acid amino acid 5 Serine Glycine 5 Serine Threonine 5 Serine Glutamate 5 Serine Alanine 13 Arginine Alanine 14 Threonine Glycine 14 Threonine Alanine 15 Glycine Alanine 12 Alanine Threonine 4 Tryptophan Serine 6 Leucine Serine

In other embodiments, a core peptide mutant of mutacin 1140 comprises or consists of a combination of mutations described in the Table 3 below.

TABLE 3 Examples of core peptide mutants of mutacin 1140 comprising SEQ ID NO: 24 or mutacin B-Ny266 comprising the sequence of SEQ ID NO: 23. For mutacin 1140, the amino acid positions are indicated with respect to SEQ ID NO: 24 and for mutacin B-Ny266, the amino acid positions are indicated with respect to SEQ ID NO: 23. Mutations in the corresponding positions of mutacin 1140 or mutacin B-Ny266 prior to post-translational modification comprising SEQ ID NO: 10 or 11, respectively, are also envisioned. Amino acid Original amino acids Replacement amino acid positions (respectively) (respectively) 12, 14  Alanine and Threonine Threonine and Glycine 13, 14  Arginine and Threonine Alanine and Alanine 14, 15  Threonine and Glycine Alanine and Alanine 5, 14 Serine and Threonine Glycine and Glycine 5, 14 Serine and Threonine Alanine and Glycine 5, 14 Serine and Threonine Threonine and Glycine 5, 14 Serine and Threonine Alanine and Serine 5, 14 Serine and Threonine Alanine and Alanine 5, 14 Serine and Threonine Glycine and Alanine 5, 14 Serine and Threonine Glutamate and Alanine 5, 14 Serine and Threonine Threonine and Alanine 5, 12 Serine and Alanine Alanine and Serine 5, 13 Serine and Arginine Alanine and Serine 13, 14 and 15  Arginine, Threonine and Alanine, Alanine and Glycine Alanine 5, 13 and 14 Serine, Arginine and Glcyine, Alanine and Threonine Alanine  4, 5 and 14 Tryptophan, Serine and Serine, Alanine and Threonine Alanine  5, 6 and 14 Serine, Leucine and Alanine, Serine and Threonine Alanine 5, 12 and 14 Serine, Alanine and Alanine, Serine and Threonine Alanine 5, 13 and 14 Serine, Arginine and Alanine, Serine and Threonine Alanine 12, 13 and 14  Alanine, Arginine and Glycine, Glycine and Threonine Glycine

In further embodiments, the invention provides a core peptide mutant of mutacin 1140 comprising SEQ ID NO: 24 or mutacin B-Ny266 comprising the sequence of SEQ ID NO: 23, with the proviso that the core peptide mutant does not contain:

i) amino acid mutations of one or any combination of the second, sixth or thirteenth amino acid residue of SEQ ID NO: 23 or 24 (i.e., the second alone, the sixth alone, the thirteenth alone, the combination of the second and sixth, the combination of the second and thirteenth, the combination of the sixth and thirteenth, or the combination of the second, sixth and thirteenth amino acid residues of SEQ ID NO: 23 or 24);

ii) mutation of one or more of Leu6 and Arg13 to an amino acid selected from alanine, glycine, valine, leucine or isoleucine;

iii) mutation of one or more of Leu6 and Arg13 to alanine; or

iv) mutation of Lys2 to an amino acid selected from alanine, glycine, valine, leucine or isoleucine.

A further embodiment of the invention provides a pharmaceutical composition comprising a modified lantibiotic or a functionalized lantibiotic described herein and a pharmaceutically acceptable carrier or excipient. Further embodiments of the invention provide a method of treating a bacterial infection in a subject by administering to the subject a modified lantibiotic or a functionalized lantibiotic described herein. The modified lantibiotic or a functionalized lantibiotic administered to a subject can be in the form of pharmaceutical compositions of the invention.

Decarboxylation of the terminal cysteine in a lantibiotic is typically performed by a decarboxylase, which is typically a flavoprotein. This decarboxylase is specific for C-terminal cysteines from a lantibiotic peptide. Decarboxylation of the C-terminal cysteine produces an ene-thiol intermediate that promotes terminal ring formation. Accordingly, a further embodiment of the invention provides a bacterium that synthesizes a modified lantibiotic. Such bacterium is produced by a genetic modification to a wild-type or a parent bacterium that synthesizes a parent lantibiotic that corresponds to the modified lantibiotic.

Accordingly, certain embodiments of the invention provide a bacterium that synthesizes a modified lantibiotic, wherein the modified lantibiotic has an intact cysteine at the C-terminus, and wherein the bacterium is genetically modified to inactivate a gene that encodes a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic.

Several bacteria are known to produce a lantibiotic, for example, Bacillus licheniformis (strain ATCC 14580), Streptomyces sp., Lactobacillus sakei, Streptococcus salivarius, Streptococcus mutans, Lactococcus lactis, Actinoplanes liguriensis, Bacillus sp., Staphylococcus epidermidis, Staphylococcus gallinarum, Streptococcus mutans or Ruminococcus gnavus. Accordingly, certain embodiments of the invention provide a bacterium that synthesizes a modified lantibiotic, wherein the bacterium is Bacillus licheniformis (strain ATCC 14580), Streptomyces sp., Lactobacillus sakei, Streptococcus salivarius, Streptococcus mutans, Lactococcus lactis, Actinoplanes liguriensis, Bacillus sp., Staphylococcus epidermidis, Staphylococcus gallinarum, Streptococcus mutans or Ruminococcus gnavus.

Non-limiting examples of bacterial strains, corresponding lantibiotics and their peptide sequences before the PTMs are provided in Table 4 below.

TABLE 4 Examples of organisms producing lantibiotic and the sequences of unmodified peptides corresponding to mature forms of lantibiotics. Propeptide Mature Name of the Sequences Sequences Name of the organism lantibiotic (SEQ ID) (SEQ ID) Bacillus licheniformis lichenicidin A2 1 14 (strain ATCC 14580) Lactobacillus sakei L45 lactocin-S 2 15 Streptococcus salivarius Salivaricin 3 16 Streptococcus mutans Mutacin-2 4 17 Lactococcus lactis lacticin 3147 A2 5 18 subsp. lactis (Streptococcus lactis) Actinoplanes liguriensis actagardine 6 19 Bacillus sp. mersacidin 7 20 (strain HIL-Y85/54728) Staphylococcus epidermidis Epidermin 8 21 Staphylococcus gallinarum Gallidermin 9 22 Streptococcus mutans mutacin B-Ny266 10 23 Streptococcus mutans mutacin-1140 11 24 Ruminococcus gnavus Ruminococcin-A 12 25 Microbispora corallina Microbisporicin 13 26

For a given bacterium that produces a lantibiotic, a person of ordinary skill in the art can determine which gene encodes a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic. For example, EpiD gene from S. epidermidis encodes for a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor epidermin. Similarly, MrsD gene from Bacullus sp. encodes for a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor mersacidin. Additional examples of decarboxylase enzymes that decarboxylate the cysteine at the C-terminus of a precursor lantibiotic in other lantibiotic producing bacteria are known in the art and such embodiments are within the purview of the invention.

A gene that encodes the decarboxylase enzyme can be inactivated in a number of genetic modification techniques. For example, a gene that encodes the decarboxylase enzyme can be inactivated by deletion, frameshift mutation(s), point mutation(s), antisense RNA, the insertion of stop codon(s), or combinations thereof. For example, target genes can be inactivated by the introduction of insertions, deletions, or random mutations into the gene that encodes the decarboxylase enzyme. Thus, certain embodiments of the invention provide for the insertion of at least one stop codon (e.g., one to ten or more stop codons) into the gene that encodes the decarboxylase enzyme. Some embodiments of the invention provide for the insertion or deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 or more bases in order to introduce a frameshift mutation in a gene that encodes the decarboxylase enzyme gene. Other embodiments of the invention provide for the insertion or deletion of 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29 or more bases in order to introduce a frameshift mutation in a gene that encodes the decarboxylase enzyme. Yet other embodiments of the subject application provide for the introduction of one or more point mutations (e.g., 1 to 30 or more) within a gene that encodes the decarboxylase enzyme while other embodiments of the invention provide for the partial, total or complete deletion of a gene that encodes the decarboxylase enzyme.

In one embodiment, a gene that encodes the decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic in a bacterium is inactivated by introducing into the bacterium an inhibitory RNA specifically directed to the gene. In certain embodiments, the inhibitory RNA is an antisense RNA that has an appropriate sequence to inhibit the expression of an mRNA that encodes the decarboxylase enzyme.

Various techniques for carrying out the genetic modifications to inactivate a gene that encodes the decarboxylase enzyme in a bacterium are well known in the art and such embodiments are within the purview of the invention.

In one embodiment, a bacterium that produces a lantibiotic contains endogenous gene cluster that encodes the lantibiotic, i.e., the bacterium naturally produces the lantibiotic. Such bacterium can be genetically modified to inactivate the gene that encodes the decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic.

In another embodiment, a bacterium that produces a lantibiotic contains exogenous gene cluster that encodes the lantibiotic, i.e., the bacterium is genetically engineered to express the gene cluster that encodes the lantibiotic. Such bacterium can be further genetically modified to inactivate the gene that encodes the decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic.

In a further embodiment, a bacterium that produces a lantibiotic through exogenous genes that encode the lantibiotic, i.e., the bacterium is genetically engineered to express the genes that encode the lantibiotic does not contain an endogenous gene that encodes the decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic. In such bacterium, genetic modification to inactivate the gene that encodes the decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic is not necessary. As such, an embodiment of the invention provides a bacterium that does not contain an endogenous gene that encodes the decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic and that contains exogenous genes that encode the lantibiotic, i.e., the bacterium is genetically engineered to express the genes that encode the lantibiotic.

A further embodiment of the invention provides a method of producing a modified lantibiotic, wherein the modified lantibiotic has an intact cysteine at the C-terminus. The method comprises the steps of:

a) culturing a bacterium that synthesizes the modified lantibiotic, wherein the bacterium is genetically modified to inactivate a gene that encodes a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic,

b) purifying the modified lantibiotic from the culture.

The embodiments of the invention discussed above with respect to a bacterium that produces a modified lantibiotic as described herein are applicable to the methods of producing the modified lantibiotic as well.

In certain embodiments, the bacterium is cultured under appropriate conditions for appropriate period of time. A skilled artisan is well-versed with the methods of culturing bacteria and such embodiments are within the purview of the invention.

A step of producing a modified lantibiotic comprises purifying the modified lantibiotic from the culture of the bacterium. Non-limiting examples of such purification methods include liquid chromatography, particularly, fast protein liquid chromatography (FPLC), high-performance liquid chromatography (HPLC), ion exchange chromatography, size-exclusion chromatography, or affinity chromatography. Additional examples of purifying a modified lantibiotic from bacterial culture are known to a skilled artisan and such embodiments are within the purview of the invention.

A further embodiment of the invention provides a method of producing a functionalized lantibiotic by reacting, under appropriate conditions, a modified lantibiotic described herein with a moiety to conjugate the moiety to the carboxyl group of the terminal cysteine. Various moieties described above in connection with the functionalized lantibiotic are also applicable to the methods of making the functionalized lantibiotics described herein.

In one embodiment, a functionalized lantibiotic is produced by 1-Hydroxy-7-azabenzotriazole/1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (HOAt/EDC) coupling method. Additional techniques for conjugating a modified lantibiotic described herein with a moiety are known to a skilled artisan and such embodiments are within the purview of the invention.

An embodiment of the invention provides a lantibiotic containing one or more amino acid mutations, wherein the lantibiotic containing the one or more amino acid mutations exhibits higher anti-bacterial activity compared to the activity of the lantibiotic being mutagenized. In one embodiment, the invention provides a mutant of a lantibiotic belonging to the epidermin group of lantibiotics, for example, mutacin (e.g., SEQ ID NOs: 4, 10 and 11), epidermin (e.g., SEQ ID NO: 9), gallidermin (e.g., SEQ ID NO: 10), that contains one or more amino acid mutations, wherein the mutant lantibiotic exhibits higher anti-bacterial activity compared to lantibiotic being mutagenized.

Non-limiting examples of a mutant of mutacin 1140 that exhibit higher antibacterial activity compared to mutacin 1140 includes mutations to one or more of Leu6 and Arg13. In one embodiment, a mutant mutacin 1140 contains mutations of one or more of Leu6 and Arg13 to an amino acid selected from alanine, glycine, valine, leucine or isoleucine. In certain embodiment, a mutant mutacin 1140 contains mutations of one or more of Leu6 and Arg13 to alanine.

Non-limiting examples of a mutant of epidermin that exhibit higher antibacterial activity compared to epidermin includes mutations to one or more of Ile6 and Lys13. In one embodiment, a mutant epidermin contains mutations of one or more of Ile6 and Lys13 to an amino acid selected from alanine, glycine, valine, leucine or isoleucine. In certain embodiment, a mutant epidermin contains mutations of one or more of Ile6 and Lys13 to alanine.

Non-limiting examples of a mutant of gallidermin that exhibit higher antibacterial activity compared to gallidermin include mutations to one or more of Lue6 and Lys13. In one embodiment, a mutant gallidermin contains mutations of one or more of Leu6 and Lys13 to an amino acid selected from alanine, glycine, valine, leucine or isoleucine. In certain embodiment, a mutant gallidermin contains mutations of one or more of Leu6 and Lys13 to alanine.

Non-limiting examples of a mutant of mutacin B-Ny266 that exhibit higher antibacterial activity compared to mutacin B-Ny266 includes mutations to one or more of Phe6 and Lys13. In one embodiment, a mutant mutacin B-Ny266 contains mutations of one or more of Phe6 and Lys13 to an amino acid selected from alanine, glycine, valine, leucine or isoleucine. In certain embodiment, a mutant mutacin B-Ny266 contains mutations of one or more of Phe6 and Lys13 to alanine.

A further embodiment of the invention provides a lantibiotic containing one or more amino acid mutations, wherein the lantibiotic containing the one or more amino acid mutations is expressed in higher amounts by the bacterium producing the mutant lantibiotic compared to the bacterium producing the lantibiotic being mutagenized.

In one embodiment, the invention provides a mutant of a lantibiotic belonging to the epidermin group of lantibiotics, for example, mutacin (e.g., SEQ ID NOs: 4, 10 and 11), epidermin (e.g., SEQ ID NO: 9), gallidermin (e.g., SEQ ID NO: 10), that contains one or more amino acid mutations, wherein the mutant lantibiotic is expressed in higher amounts by the bacterium producing the mutant lantibiotic compared to the bacterium producing the lantibiotic being mutagenized.

In one embodiment, the invention provides a bacterium producing a mutant of mutacin 1140 (SEQ ID NO: 11) containing one or more amino acid mutations, wherein the mutant of mutacin 1140 is expressed in higher amounts by the bacterium producing the mutant mutacin 1140 compared to the bacterium producing mutacin 1140.

Non-limiting examples of a mutant mutacin 1140 that are expressed in higher amounts include a mutation of Lys2. In one embodiment, a mutant mutacin 1140 contains mutations of Lys2 to an amino acid selected from alanine, glycine, valine, leucine or isoleucine. In certain embodiment, a mutant mutacin 1140 contains a mutation of Lys2 to alanine.

Non-limiting examples of a mutant mutacin B-Ny266 that are expressed in higher amounts include a mutation of Lys2. In one embodiment, a mutant mutacin B-Ny266 contains mutations of Lys2 to an amino acid selected from alanine, glycine, valine, leucine or isoleucine. In certain embodiment, a mutant mutacin B-Ny266 contains a mutation of Lys2 to alanine.

Certain embodiment of the invention provides a pharmaceutical composition comprising a mutant lantibiotic described herein and a pharmaceutically acceptable carrier or excipient. Further embodiments of the invention provide a method of treating a bacterial infection in a subject by administering to the subject a mutant lantibiotic described herein. The mutant lantibiotic administered to a subject can be in the form of pharmaceutical compositions of the invention.

Further embodiments of the invention provide a bacterium expressing a mutant lantibiotic, particularly, a mutant mutacin 1140 that exhibits higher activity compared to mutacin 1140 or a mutant mutacin 1140 that exhibits higher expression by a bacterium compared to mutacin 1140. Various embodiments discussed above with respect to mutants of mutacin 1140 are also applicable to a bacterium expressing a mutant mutacin 1140. A skilled artisan can readily design a bacterium expressing a mutant mutacin 1140 by transforming a bacterium with a gene or a gene cluster encoding a mutant mutacin 1140 and such embodiments are within the purview of the invention.

Materials and Methods

Bacterial Strains and Media

The bacterial strains and plasmids used in this study are outlined in Table 5. Streptococcus mutans strains, Bacillus subtilis PY79, Streptococcus pneumoniae, and Micrococcus luteus ATCC 10240 were grown in either THyex media agar (30 g/L Todd Hewitt Broth, 3 g/L yeast extract, 15 g/L agar; Bacto, Sparks, Md.), THyex broth (30 g/L Todd Hewitt Broth, 3 g/L yeast extract), or THyex top agar (30 g/L Todd Hewitt Broth, 3 g/L yeast extract, 7.5 g/L agar; Bacto, Sparks, Md.). E. coli was grown in LB medium (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl, pH adjusted with NaOH to pH 7.5), Terrific Broth (12 g/L tryptone, 24 g/L yeast extract, 4 mL/L glycerol, and 2.2 g/L KH₂PO₄ and 9.4 g/LK₂HPO₄), or LB plates (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl, 15 g/L agar, and pH adjusted with NaOH to pH 7.5).

TABLE 5 Strains used in this study. Plasmid Relevant Reference Strain intermediate characteristic or Source S. mutans JH1140 WT bacteriocin Strain 1, (ATCC 55676) producing strain ATCC S. mutans ΔmutA mutA deletion 2 strain S. mutans IFDC2:mutD mutD gene This study replacement with IFDC2 cassette S. mutans ΔmutD pΔmutD Clean deletion of This study mutD M. luteus ATCC 10240 Indicator strain 3 for activity B. subtilis PY79 Indicator strain 4 for activity S. pneumoniae ATCC Indicator strain ATCC 27336 for activity E. coli DH5α pCR2.1 and Intermediate Invitrogen pET28B(+) cloning host E. coli BL21 Protein over- Invitrogen expression host E. coli pmutD-kan pmutD-kan Codon optimized This study mutD E. coli pet28B:mutD pet28B:mutD MutD This study overexpression strain

Gene Deletion of MutD

Primers used for both sequencing and mutagenesis were designed using the S. mutans genome and lan cluster (GenBank/EMBL accession number AF051560) (Table 6). The IFDC2 gene replacement system was used, as previously described, to mutate or delete MutD³⁰. In-frame deletion cassette (IFDC2) is a gene replacement cassette containing both a positive selection marker (ermAM) and a negative selection marker (pheS*). Approximately 500 bp upstream of mutD was amplified and to prevent polar effects of downstream genes of mutD, a 500 bp fragment was amplified starting at 100 bp upstream of the stop codon and 400 bp downstream of mutD. The fragments were attached to the 5′ and 3′ end of the IFDC2 cassette, respectively, by PCR. The final 3 kb fragment was transformed into S. mutans ATCC 55676 by competent stimulating peptide (CSP) protocol⁵⁷. An overnight culture of S. mutans ATCC 55676 was diluted to 0.1 OD⁶⁰⁰ and incubated at 37° C. to 0.25 OD⁶⁰⁰. Two μl of 10 μg/mL solution of CSP was then added to 200 μl of the 0.25 OD culture. After a 30 minute incubation time at 37° C., 1 μl of the PCR amplified product was added to the culture. The transformation was incubated at 37° C. for 5 hours before plating 50 μl of a 1000-fold dilution onto a THyex plate containing 15 μg/mL of erythromycin. Transformants were confirmed by PCR. The PCR products were inserted into a Topo PCR2.1® plasmid and were sent for sequencing. Both upstream and downstream regions were joined together and amplified to create the ΔmutD fragment. The ΔmutD fragment was transformed into S. mutans IFDC2:mutD, and selected on THyex plates (containing 4 mg/mL of P-Chlorophenylalanine).

TABLE 6 Primers used in this study. Character- Primer Sequence (5′ to 3′) istic MutD-UpF GAT TTG TTT CGT AAA GAG GGT mutD gene TC (SEQ ID NO: 27) replacement MutD-DnR CTA CAT CAA TCC CAG AAT CAA mutD gene C (SEQ ID NO: 28) replacement MutD-UpR- GAGTGTTATTGTTGCTCGGAAATTATT mutD gene IDH TCTCCGTTCAG TTAA (SEQ ID replacement NO: 29) MutD-DnF- GGTATACTACTGACAGCTTCGGTAATT mutD gene erm GTTGGACAAGAATC (SEQ ID NO: replacement 30) DelMutD-F TTAACTGAACGGAGAAATAATTGGTAA mutD clean TTGTTGGACAAGAATC (SEQ ID deletion NO: 31) DelMutD-R GATTCTTGTCCAACAATTACCAATTAT mutD clean TTCTCC GTTCAGTTAA (SEQ ID deletion NO: 32)

Bioactivity Assays

The deferred antagonism assay was performed as previously described³⁹ . S. mutans strains were grown overnight in THyex broth at 37° C. The cultures were diluted to 0.1 OD OD₆₀₀ and grown to mid-logarithmic phase before diluting to 0.05 OD₆₀₀. Then, 2 μl of the cultures were spotted on THyex plates in duplicates of triplicates. The wild-type S. mutans JH1140 and S. mutans ΔmutA were used as positive and negative controls for activity, respectively. The plates were incubated for 18 hours in a candle jar at 37° C. After incubation, the strains were heat killed at 65° C. for 90 minutes. Fresh M. luteus grown overnight at 37° C. on THyex plates were used to inoculate pre-warmed THyex broth. The culture was grown to 0.6 to 0.8 OD before diluting to 0.2 OD₆₀₀. The culture was further diluted 25-fold in melted (42° C.) THyex top agar. Approximately 5 mL of the top agar solution was spread on the heat killed bioassay plates and allowed to cool for 10 minutes. The plates were then placed in the incubator (at 37° C.) for 18 hours.

Minimum Inhibitory Concentrations (MICs) were determined according to previously published protocol³¹. A stock solution of the antibiotics tested was first suspended in 50% acetonitrile (ACN) at a concentration 640 μg/mL. This stock was subsequently diluted 2-fold until a final concentration 0.156 μg/mL was reached. Subsequently, 10 μl of each dilution was placed into a well on a 96 well microtiter plate. M. luteus ATCC 10240, S. pneumoniae, and B. subtilis PY79 were grown overnight in THyex at 37° C. Cultures were diluted in the morning to 0.1 OD₆₀₀ and allowed to grow to 0.6 OD₆₀₀. This culture was diluted a 100-fold in fresh THyex media and then 400 μl of this culture was added to 10 mL of fresh THyex. The suspension contains approximately 10⁵ colony forming units (CFUs). The bacterial suspension (190 μL) was added to each well containing 10 μL of antibiotic suspension or solvent blank. This resulted in another 20-fold dilution of the antibiotic suspension. For the competition assays, 10⁵ CFU bacterial suspension was initially mixed with mu1140-COOH for 15 minutes at the 1×MIC of either mutacin 1140 (0.25 μg/mL and 0.125 μg/mL for B. subtilis and M. luteus, respectively) or nisin (0.5 μg/mL for B. subtilis and M. luteus). Following the 15 minute pretreatment, 190 μL was added to each well as described above. The MIC is described as the highest concentration of antibiotic that prevented visible growth after 24 hours.

Production and Purification of Mutacin 1140 and Mu1140-COOH

Lanthipeptides isolated in this study were cultured as stated previously⁵⁸ . S. mutans strains were grown in a modified THyex media. The media contained 30 g/L Todd Hewitt, 3 g/L yeast extract, 1 g/L NaH₂PO₄, 0.2 g/L Na₂HPO₄, 0.7 g/L MgSO₄, 0.005 g/L FeSO₄, 0.005 g/L MnSO₄, and 0.3% agar. The semi-solid agar (1 L) was inoculated with various strains of S. mutans and incubated at 37° C. for 72 hours. After incubation, the inoculum was frozen at −80° C. overnight and thawed for 1 hour in a 65° C. water bath. The inoculum was then centrifuged at 20,000 g for 30 minutes and the supernatant was collected. The supernatant was mixed with chloroform at 1:1 ratio and mixed vigorously. This mixture was again centrifuged at 20,000 g for 30 minutes. The precipitate between both the aqueous and chloroform phases was collected and dried overnight. The dried product was resuspended in 35% ACN containing 0.1% trifluoroacetic acid (TFA) and ran on either a semi-prep C18 column (Agilent® ZORBAX, ODS, C18, 5 μm, 4.6×250 mm) or analytical column. Peaks collected were confirmed by mass on a Shimadzu® MALDI-MS on both linear and reflectron modes.

Chemical Modification of Mu1140-COOH and Nisin

Labeling of C-terminal carboxyl group with methylamine (33% in EtOH) (Sigma-Aldrich), diaminoheptane (Sigma-Aldrich), chlorophenylalanine (Sigma-Aldrich), di-chlorophenylalanine (Sigma-Aldrich), or 5-(aminoacetamido)fluorescein (Sigma-Aldrich) was done by 1-Hydroxy-7-azabenzotriazole/1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (HOAt/EDC) coupling. The labeling was done in according to a previously described method^(16, 39). The reaction mixture was suspended in 100 μl of Dimethyl Formamide (DMF) with 50 nmols of either nisin, or Mu1140-COOH, 50 nmols AAA-fluorescein or 200 nmols of the primary amine, 60 nmols of 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), and 60 nmols of 1-Hydroxy-7-azabenzotriazole (HOAt). The reaction was covered in foil and incubated at room temperature for approximately 16 hours. The reaction was subsequently diluted 10-fold with 35% ACN containing 0.1% TFA and ran on an analytical C-18 column. The labeled peptides were confirmed by MALDI-MS as described above. The amount of chemically conjugated product was determined by Bradford Assay using manufacturer recommended protocol (Sigma-Aldrich). The purified labeled peptides were then dried down and resuspended in 35% ACN containing 0.1% TFA at a concentration of 100 ug/mL and stored at −20° C.

Microscopy

B. subtilis PY79 was grown and treated with fluorescein labeled peptide as previously described³⁹. A fresh plate of B. subtilis was used to inoculate THyex broth and incubated approximately 16 hours at 37° C. The culture was diluted 20-fold and placed back in the incubator for 3 hours at 37° C. Then, 100 μl of the culture was incubated with the antibiotic (10 μg/mL) for 15 minutes. The cells were pelleted and resuspended in 100 μl of phosphate buffer solution (PBS). The wash step was repeated three times before fixing with 1.6% formaldehyde in PBS. After fixation the cells were washed with PBS three more times and the remaining pellet was suspended in 50 μL of PBS. The sample (30 μL) was added to a slide and observed using an Olympus confocal microscope with a 100×/0.90 dry objective. A 488 nm argon laser was used to excite the fluorophore. For the competition assay, the bacterial culture was initially incubated with mu1140-COOH or native mutacin 1140 at a concentration of 10 μg/mL for 15 minutes, washed, and resuspended in fresh media. 10 μg/mL of fluorescein labeled nisin was then added for 15 minutes, before following the wash protocol previously stated.

Mu1140 Double Labeling and Edman Sequencing

Edman sequencing has been frequently used to determine the sequence of small peptides, such as lantibiotics⁵⁹⁻⁶⁰. Mu1140-COOH was doubly labeled as previously described for mutacin 1140³². A 200 μM solution of Mu1140-COOH in 5 μl of water was added to a reaction tube containing 2 mg of sodium borohydride. Then, 94 μL of solution B (570 mg guanidine HCl, 100 mL N-ethylmorpholine and water to a final volume of 1 mL; the pH of the mixture was adjusted to 8.5 with glacial acetic acid) was added to the reaction mixture and placed into a glass vial. The reaction vial was purged with nitrogen and stored at 37° C. for three days. The peptide was then loaded onto a prosorb column (Applied Biosystems) and absorbed onto a PVDF membrane. After drying the PVDF membrane, 15 μl of solution A (280 μL methanol, 200 μL water, 65 μL 5 M sodium hydroxide, 60 μL ethanethiol) was added to the membrane. The reaction was sealed tightly and incubated at 50° C. for 1 hour. After the reaction, the sample was sent out for Edman sequencing. The glass fiber filter used in the Edman sequencing was pretreated with polybrene to reduce the loss of peptide per cycle. After drying in nitrogen, the PVDF membrane was excised and loaded onto a sequencer (Applied Biosystems 492 Protein P.E. Biosystems, Foster City, Calif., USA). The sequence was analyzed by the ABI 610A data software. D,L-2-aminobutyric acid was commercially purchased from Sigma Aldrich and used as a standard.

MutD Cloning and Purification

A codon optimized sequence of mutD for E. coli was purchased from Integrated DNA Technologies (IDT, Coralville, Iowa). According to manufacturer's specifications, mutD gene was cloned into the Xhol site within the pET28B(+) expression vector (EMD Millipore, Billerica Mass.) providing an N-terminal His-tag. The ligation was transformed into E. coli DH5α and confirmed by sequencing. The plasmid was then transformed into the E. coli BL21 expression strain. A fresh plate of E. coli BL21 pET28B(+):mutD was restreaked onto LB plate containing 50 μg/mL kanamycin (kan) prior to induction. One colony from the plate was suspended in 1 L of Terrific broth containing 50 μg/mL kan. Before the addition of IPTG (250 ul of a 1M solution), the culture was shaken at 37° C. until an OD₆₀₀ of 0.8 was reached. Following induction, the culture was incubated with shaking at 18° C. for approximately 16 hours. The culture was then spun at 4000 g for 30 minutes at 4° C. The pellets were resuspended in 25 mL of lysis buffer (500 mM NaCl, 50 mM Tris-HCl, 15 mM imidazole, 1 mM PMSF, 10% glycerol, at pH 7.5), before adding 500 μl of the lysozyme solution (50 mg/mL). The solution was mixed and stored on ice for 30 min. The suspension was lysed using a sonicator at medium setting for 10 minutes with 1 minute intervals, taking care to not overheat the solution. The lysate was then centrifuged at 16,000 g and the supernatant was collected. 500 μl of Ni-NTA beads were added to the supernatant and placed on a shaker for approximately 16 hours at 4° C. The Ni-NTA beads were collected by centrifugation at 3,000 RPM for 10 minutes at 4° C. The beads were washed three times with 10× bead volume of lysis wash buffer (500 mM NaCl, 50 mM Tris-HCl, 30 mM imidazole, 1 mM PMSF, at pH 7.5). After washing, the beads were eluted by resuspending in 500 μL of lysis buffer containing 0.5 M Imidazole. The suspension was place on a shaker for 1 hour at 4° C. and the elution was repeated three times. The elutions were run on an SDS Page gel to determine purity of the MutD. The decarboxylase was further run on an FPLC. Protein concentrations were determined by Bradford assay (Sigma-Aldrich).

In Vitro Decarboxylation

In vivo decarboxylation was performed as previously described²¹. A control substrate, SFNSYTC was purchased from Peptide&Elephants. 1 mg/mL solution of either SFNSYTC or mu1140-COOH in Tris-HCl buffer (pH 8.0) containing 3 mM DTT was prepared. The peptide solution (100 μL) was incubated with MutD (30 μg/mL) for 1 to 10 hours at 37° C. The sample was diluted 10-fold in 35% ACN containing 0.1% TFA before being loaded on the RP-HPLC as previously described³¹. The masses of the isolated fractions were determined by MALDI-TOF.

Lipid II Binding Assay

Lipid II was a kind gift from Eefjan Breukink and was resuspended in a 1:1 Methanol:Chloroform solution. The lipid II binding assay using thin layer chromatography (TLC) was done as previously described³⁹. The mobile solvent consisted of consisted of butanol:acetic acid:water:pyridine (15:3:12:10 [vol/vol/vol/vol]). A 0.2 mM solution of mutacin 1140 or mu1140-COOH in 10 μL of solution A was mixed with lipid II (final 6.8 mM) for 1 hour in a sealed glass vial. This corresponded to a ratio 3:10 peptide:lipid II ratio. All of the reaction mixtures and the appropriate controls were spotted (5 μL) 2 cm from the bottom of the plate. These spots define the origin of the plate. Lipid II and peptide alone were used as a control to demonstrate that the origins do not stain unless peptide and lipid II are added together. The mobile phase was allowed to climb up the plate until it reached a centimeter from the top. The plate was allowed to dry before staining with iodine.

All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

Following are examples which illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1—Engineering a C-Terminal Carboxyl Analog of an Epidermin Group Lantibiotic

A C-terminal carboxyl analog for the epidermin group of lantibiotics has not yet been characterized. Several structural analogs of mutacin 1140 were identified when the formation of ring B was disrupted by a C(11)A mutation. The mutation interfered with the formation of the PTMs normally found within mutacin 1140 and one of the peptide analogs had not undergone a C-terminal decarboxylation²⁹. This observation supported the basis for engineering S. mutans JH1140 to produce a mutacin 1140 C-terminal carboxyl analog (mu1140-COOH). Deletion or insertional mutagenesis of mutD was done using the IFDC2 gene replacement system (FIG. 5a )³⁰. A deferred antagonism assay, using the indicator strain Micrococcus luteus ATCC 10240, was performed on the S. mutans insertional IFDC2:mutD and S. mutans ΔmutD mutant strains. Neither mutant strains had a clear zone of inhibition (FIG. 5b ), suggesting that the mutants did not produce a product or that the product was inactive. The culture broth of each mutant was extracted using the same extraction method for wild-type mutacin 1140. These extracts were run on an HPLC, as previously described³¹. There was no observable product for the ΔmutD strain. The ribosomal binding site (RBS) for mutP protease is within the 3′ end of the mutD gene. Careful consideration was made to leave the RBS site in the deletion strain. However, there may be other elements important for the synthesis of downstream products that are not readily apparent. Nevertheless, a single HPLC peak for IFDC2:mutD strain was isolated and further characterized (FIG. 5c ). The IFDC2 cassette is under the control of a constitutive lactose dehydrogenase (ldh) promoter and this promoter may facilitate the expression of the downstream genes. The purified product from this mutant was analyzed by MALDI-TOF mass spectrometry and had a mass of 2310 Da. This mass corresponded to the expected mass of a C-terminal carboxyl analog of mutacin 1140. A minimum inhibitory concentration (MIC) assay performed using mu1140-COOH analog against M. luteus revealed a 256-fold reduction in activity compared to wild type mutacin 1140. Furthermore, the activity of mu1140-COOH against Streptococcus pneumoniae ATCC 27336 was greater than 64 μg/mL, which is more than a 128-fold reduction in activity (Table 7). The loss in activity in the MIC assays further corroborates the lack of activity seen in the deferred antagonism assays. The reason for the lack of activity may be attributed to the presence of the carboxyl group or it could indicate that the presence of the carboxyl group has disrupted the occurrence of other PTMs found in mutacin 1140.

TABLE 7 Mass and activity of chemically modified analogs of mutacin 1140 against select bacteria. Expected Observed MIC MIC Mutacin 1140 Mass Mass (μg/mL) (μg/mL) analog (Da) (Da) M. luteus S. pneumoniae Mutacin 1140 2264.63 2264.63 0.125 0.5 Mu1140 - COOH 2310.65 2310.63 32 >64 Mutacin 1140 - 2325.72 2325.42 0.125 0.5 methylamine Mutacin 1140 - 2422.88 2421.97 0.25 2 diaminoheptane Mutacin 1140 - 2436.25 2435.80 1 8 chlorophenylalanine Mutacin 1140 - 2470.69 2468.26 4 8 di- chlorophenylalanine

MALDI-TOF mass analysis can determine dehydrations due to an observable change in mass. It cannot determine the formation of a lanthionine ring after dehydration, since the PTM does not result in a change in mass of the peptide. Therefore, the formation of the lanthionine rings was assessed by another method. A rapid and straight forward Edman sequencing method has been developed to distinguish between dehydrated residues and dehydrated residues involved in lanthionine ring formation³². Dehydrated residues are first hydrated by sodium borohydride before lanthionine ring derivatization by an organothiol compound. This method can determine where the lanthionine rings are formed and the location of all the dehydrated residues, thus, elucidating the covalent structure of the lantibiotic peptide. Sodium borohydride reduction of Dha and Dhb residues result in the formation of alanine and 2-aminobutyric acid, respectively. Subsequent ethanethiol derivatization open the lanthionine rings, which form either thioethyl cysteines (S-EC) or β-methylthioethyl cysteines (β-M-S-EC). The presence of an S-EC or BM-S-EC residue at the amino acid positions 3, 8, 16, and 19 indicate that the free thiols of upstream cysteines had reacted with their downstream dehydrated residues to form a lanthionine ring. Alanine and 2-aminobutyric acid were observed in positions 5 and 14, respectively (FIG. 6). These correspond to the reduction of the Dha5 and Dhb14 residues. S-EC or BM-S-EC residues were observed in the expected amino acid positions 3, 8, 16, and 19 (FIG. 6), confirming that they are involved in lanthionine ring formations. These data suggest that the loss of activity is not due to disruptions to the other PTM's and that the observed loss in bioactivity of the mu1140-COOH analog is due to the presence of a C-terminal carboxyl group.

These results also demonstrate that the presence of the AviCys residue is not essential for the activity of a lantibiotic; however, the removal of the carboxyl group of the cysteine at the C-terminus is essential for the activity of a lantibiotic.

Example 2—Restoration of Bioactivity of the C-Terminal Carboxyl Analog of an Epidermin Group Lantibiotic

Removal of the carboxyl group by MutD was attempted to confirm that the presence of the C-terminal carboxyl group is responsible for the loss in bioactivity. A C-terminal histidine tag of MutD was constructed and overexpressed in Escherichia coli. The purified product on an SDS-PAGE gel had the expected monomer size of 25 kDa; however, subsequent purification through FPLC showed a product that was approximately 200 kDa. 200 kDa mass is consistent with the formation of a homododecamer, as was previously reported for the epidermin decarboxylase EpiD²³. To determine if the enzyme was active, a reference peptide SFNSYTC was incubated with MutD for one hour. A mass of 797.67 Da determined by MALDI-TOF was observed for the reference peptide compared to 843.69 Da for the unreacted peptide, indicating that the decarboxylase was active (Table 8). mu1140-COOH analog was incubated with MutD for one or ten hours and showed no indication of a mass change by MALDI-TOF (Table 8). MutD was not capable of decarboxylating the mu1140-COOH analog.

TABLE 8 Mass of mu1140-COOH and control peptide after in vitro decarboxylation with MutD. Mass before reaction Expected mass Observed mass Substrate (Da) (Da) (Da) SFNSYTC 843.69 797.67 797.67 (1 hr) Mu1140-COOH 2310.37 2265.37 2310.63 (1 hr) Mu1140-COOH 2310.37 2265.37 2310.63 (10 hr)

Given that MutD was not capable of removing the C-terminal carboxyl group, the C-terminal carboxyl group was chemically modified and tested to determine whether C-terminal substitutions could restore the bioactivity. EDC coupling of primary amines was used to cap the C-terminal carboxyl group (FIG. 2). None of the primary amines, tested on their own, had any activity against the indicator strains used in this study. EDC coupling with methylamine, the smallest primary amine, was first attempted. The conjugation with methylamine yielded a product with a mass of 2321 Da, indicating that the reaction occurred (Table 7). Based on the RP-HPLC spectra, the reaction did not yield any other side products and the methylamine product was greater than 95% of the material. There was a small amount of unreacted mu1140-COOH analog eluting before the conjugated methylamine product. The methylamine conjugated mutacin 1140 analog had an MIC of 0.125 μg/mL against M. luteus, and 0.5 μg/mL MIC against S. pneumoniae. These values were the same as the MIC values for native mutacin 1140. These results show that capping mu1140-COOH with a small primary amine restores activity to wild type levels. This data also supports the notion that the presence of a C-terminal carboxyl group is responsible for the reduction in mu1140 activity.

mu1140-COOH was then conjugated with diaminoheptane. The activity of the diaminoheptane conjugate was 0.5 μg/mL against M. luteus and 2.0 μg/mL against S. pneumoniae. The addition of two different chlorinated aromatic rings with mu1140-COOH was also tested. The activity of chlorophenylalanine conjugate was 1.0 μg/mL against M. luteus and 2.0 μg/mL against S. pneumoniae. For the di-chlorophenylalanine conjugate, the activity was 1.0 μg/mL and 8.0 μg/mL against M. luteus and S. pneumoniae, respectively. All the conjugates restored the activity of the mu1140-COOH analog, supporting the synthesis of a library of analogs that can be screened for novel applications.

Fluorescently labeled nisin, containing a C-terminal conjugate of fluorescein, has been shown to form lipid II patches on the surface Bacillus subtilis cells¹⁶. The binding of lipid II by an epidermin group of lantibiotics has been shown in various in vitro assays³³; however, the bioactivity has never been visualized in vivo. This is due to the lack of amenable attachment site for a fluorophore. The free carboxyl group on the mu1140-COOH analog provides one such site. A C-terminal fluorescein conjugate of mutacin 1140 was evaluated. The product had the expected mass of 2623 Da and has the inhibitory activity in a deferred antagonism assay. For comparison, a C-terminal fluorescein conjugate of nisin was also made as previously described¹⁶. As shown by Hasper et al., B. subtilis cells incubated with fluorescein labeled nisin showed large green patches on the cell surface (FIG. 3). The green patches have been attributed to lipid II abduction and sequestration by nisin from its normal physiological location. The C-terminal fluorescein labeled mutacin 1140 produces a similar pattern of fluorescent patches as observed by nisin (FIG. 3). This data supports in vitro data from the epidermin group of lantibiotics for lipid II binding and sequestration and also demonstrates that this group of lantibiotics does sequester lipid II from its normal physiological location for cell wall synthesis.

Example 3—the Loss of Activity for the C-Terminal Carboxyl Analog of Mutacin 1140

With the loss of activity associated with a free carboxyl group in mu1140-COOH, the basis for the loss in activity was studied. The mechanism of action for class I lantibiotics has been determined to be due to lipid II binding³⁴⁻³⁶. In particular, rings A and B are believed to form a cage-like structure around the pyrophosphate moiety of lipid II³⁷. The latter half of the peptide is predicted to enhance binding and recruit other lipid II-lantibiotic molecules into a large lipid II-lantibiotic complex¹⁶. Given that lipid II binding is done by the N-terminal rings A and B, it is likely that the loss of activity is due to a loss in the lateral assembly function of the latter half of the peptide. To test for this assumption, a series of experiments were performed to determine whether the mu1140-COOH would bind to lipid II or competitively block lipid II binding of nisin in vivo. A TLC plate assay was used to determine if mu1140-COOH could bind to lipid II, as has been previously reported for gallidermin³⁸. If lipid II migration on the TLC plate is impeded by binding to mutacin 1140 or mu1140-COOH, an iodine stained spot is observed at the origin. No stain was visible for mutacin 1140, mu1140-COOH, and lipid II, when the compounds were spotted alone. A stained spot did appear at the origin when mutacin 1140 and mu1140-COOH were spotted with lipid II (FIG. 7). The mu1140-COOH analog mixed with lipid II showed a faint stain compared to lipid II mixed with wild-type mutacin 1140. The faint staining may be attributed to a weaker association of mu1140-COOH with lipid II than mutacin 1140. If mu1140-COOH is capable of binding to lipid II, but does not inhibit cell growth, it may provide resistance to a bacterium against mutacin 1140 or nisin. A competition MIC for mutacin 1140 and nisin was then performed against B. subtilis and M. luteus that were pretreated with mu1140-COOH. B. subtilis and M. luteus were pretreated with mu1140-COOH at 0.25 μg/mL and 0.125 μg/mL, respectively, before adding mutacin 1140. Mu1140-COOH competitively inhibited the activity of mutacin 1140 against B. subtilis and M. luteus by 4-fold (MIC 1.0 μg/mL and 0.5 μg/mL, respectively) (Table 9). When pretreated with 0.5 μg/mL of mu1140-COOH, the activity of nisin was competitively inhibited against B. subtilis and M. luteus by 4-fold and 2-fold, respectively (MIC 2.0 μg/mL and 1.0 μg/mL). To further clarify a mechanism of action for the loss of activity in the MIC competition assay, confocal microscopy was used to observe nisin binding as previously described³⁹. If mu1140-COOH is still binding to lipid II in vivo, it should competitively inhibit the binding of fluorescein labeled nisin (FIG. 4). When the bacteria were pretreated with wild-type mutacin 1140 or mu1140-COOH, no typical in vivo fluorescence pattern was observed for the fluorescein labeled nisin (FIG. 4). However, there was some association of fluorescein labeled nisin with the bacteria, but nothing remotely similar to fluorescein labeled nisin on its own. This may be due to the weaker association of mu1140-COOH to lipid II, which further corroborates the weak association with lipid II observed in the TLC assay. These results suggest that the loss in activity is not due to its inability to bind to the lipid II target, but due to its inability to form the large lantibiotic lipid II complexes.

TABLE 9 Competition MICs of mutacin 1140 or nisin against B. subtilis and M. luteus preincubated with mu1140-COOH. B. subtilis B. subtilis M. Luteus M. Luteus MIC comp. MIC MIC comp. MIC Antibiotic (μg/mL) (μg/mL) (μg/mL) (μg/mL) Mutacin 0.25 1.0 0.125 0.5 1140 Nisin 0.5 2.0 0.5 1.0

Example 4—Mutacin 1140 is Post-Translationally Modified Despite Decarboxylation at the C-Terminus

Decarboxylation in mutacin 1140 is not needed for the other PTM modifications; a fully modified analog of mutacin 1140 with a C-terminal carboxyl group (mu1140-COOH) can be isolated and purified and the bactericidal activity can be restored by labeling the carboxyl group with a primary amine. Also, a fluorescein conjugated mutacin 1140 can be synthesized, enabling in vivo visualization of mutacin 1140 bound to lipid II target. Further, the loss of activity of the mu1140-COOH analog is likely due to the carboxyl group disrupting mutacin 1140 lipid II complex formation and not due to the complete loss of lipid II binding. A lateral assembly mechanism that traps lipid II into a complex for bactericidal activity may be necessary, which is distinct for other lipid II binding antibiotics, i.e. vancomycin⁴⁰. Furthermore, at generating a C-terminal labeled library of mutacin 1140 analogs may expand the lantibiotics' application or therapeutic use.

A variant of the epidermin group of lantibiotics with a C-terminal carboxyl group is provided. Deletion of EpiD did not show activity; however, no discussion of an isolated product was mentioned²⁵. This is presumably due to the lack of a product as was observed in the mutD deletion strain. Increasing activity or developing new uses for existing lantibiotics has been a goal of many researchers in the field. This has been achieved through a variety of methods, such as amino acid substitutions and the use of non-proteogenic amino acids^(26, 41-42). Semi-synthetic analogs of lantibiotics have been produced by chemically modifying lantibiotics⁴³⁻⁴⁴. The most common chemical modification of lantibiotics is through reactions with a free C-terminal carboxyl group. NVB302, is one such variant that has been chemically modified to have a diaminoheptane tail. This analog of actagardine has made it through phase I clinical trials²⁷. Until the isolation of the mu1140-COOH analog, the presence of an AviCys residue on the epidermin group of lantibiotics prevented further development of novel analogs. The addition of a chlorinated aromatic ring may confer additional characteristics to mutacin 1140, as is seen in vancomycin analogs in which the vancomycin analog inhibited transglycosylase activity⁴⁵. Additionally, a diaminoheptane tail was conjugated to mutacin 1140, similar to NVB302. All of these analogs were bioactive.

Visualization of the bioactivity by the epidermin group of lantibiotics was limited to in vitro assays due the inability to conjugate a detectable label, for example, a fluorescent probe, to the antibiotic³³. The addition of a fluorescein label to mutacin 1140 allows the in vivo visualization of this class of lantibiotic in action. These data have provided new insights into the importance of decarboxylation for bioactivity of the epidermin group of lantibiotics. Class I lantibiotics are known to bind to lipid II by forming a cage around the pyrophosphate residue using rings A and B (the lipid II binding domain)^(37, 46). Furthermore, the latter half of the peptide is believed to help in the lateral assembly of the lantibiotic-lipid II complexes to form islands^(16, 47). In nisin, these islands form a pore complex; however, the epidermin group primarily sequesters lipid II without forming a pore, as has been reported in fluorescently labeled lipid II vesicle experiments^(16, 48). Decarboxylation has been thought to be primarily important for stability of the peptide by preventing carboxypeptidases from degrading the lantibiotic⁴⁹. The loss of activity in the mu1140-COOH analog is intriguing and is likely to be the result of various factors; however, the data provided herein suggest that the loss in activity is primarily attributed to loss in lateral assembly function. Microscopy studies show that mu1140-COOH can competitively bind to lipid II against nisin. Nisin and mutacin 1140 have been shown not to interact with each other, indicating that the decrease in fluorescence by the fluorescein labeled nisin analog was due to competition with the lipid II target³³. Additionally, the mu1140-COOH analog was shown to have a protective function against wild-type mutacin 1140 and nisin. This suggests that the lateral assembly activity is crucial for bactericidal activity and the presence of the C-terminal carboxyl group prevents mutacin 1140 forming a stable lipid II complex.

The influence of dehydrations and lanthionine ring formations on lantibiotic biosynthesis is well known⁵⁰⁻⁵¹. Yet, little is known on how other PTMs influence the biosynthesis of a functional lantibiotic. Studies have suggested that other PTM modifications, such as the N-terminal lactate of epilancin 15×, act independently of the dehydration and cyclase modifications found in lantibiotics^(3, 52-54). Previous data suggest that decarboxylation must occur before terminal ring formation due to a reactive ene-thiol intermediate that promotes terminal ring formation²⁴. A crystal structure of MrsD has suggested that its active site cannot accommodate a lanthionine ring²³. Furthermore, attempts at decarboxylation of a lanthionine mimic proved futile²¹. The lack of in vitro decarboxylation of mu1140-COOH shows that decarboxylation must occur before ring D formation suggesting that MutD cannot accommodate the terminal lanthionine ring into its active site. Additionally, the isolation of the fully modified mu1140-COOH analog demonstrates that terminal ring formation can occur regardless of the presence of a carboxyl group.

During in vivo synthesis of mutacin 1140, mutations that prevent ring formation or dehydrations within the lantibiotic may affect other PTMs within the peptide²⁹. A better understanding of the role of each PTM would promote the synthesis of novel analogs. The bioactivity of the mu1140-COOH variant can be restored by capping the C-terminus with an amine (Table 7). The chemical synthesis of the AviCys residue is cumbersome⁵⁵⁻⁵⁶. However, chemical synthesis of this residue is not necessary for the epidermin group of lantibiotics and that solid phase peptide synthesis (SPPS) with differentially protected lanthionine can be used to synthesize this class of lantibiotics. Thus, the invention described herein provides new possibilities for synthesizing novel analogs of the epidermin group of lantibiotics. Furthermore, the importance of decarboxylation for bioactivity is demonstrated.

Example 5—Site Directed Mutagenesis of Mutacin 1140 and its Effect on Bactericidal Activity

Streptococcus mutans ATCC 55676 (wild-type) and the mutants that were at an OD₆₀₀ of 0.2 were spotted in triplicates on a pre-warmed THyex agar plate (150×15 mm) and allowed to dry. This assay was performed in this manner to ensure that each sample had the same colony size for comparing zones of inhibition. The plate was incubated for 24 hours then placed in an oven at 50° C. for thirty minutes to kill the bacteria before the indicator strain was overlaid. Heat killing the bacteria prevents any further antimicrobial compound production so that results seen are from single day incubation. Zone diameter was measured in millimeters across the plate and compared to wild-type (i.e. zone I for ATCC compared to zone I of Trp4Ala, etc.).

Lys2Ala, Leu6Ala, and Arg13Ala zones were statistically significantly from the wild-type mutacin 1140 producing strain (FIG. 8). These mutants led to a larger zone of inhibition and suggest that the bacterium is producing more of the product or the antibiotic is more active. The Thr(Dhb)14Ala and Gly15Ala mutant had no change in activity relative to wild-type strain.

Mutacin 1140 variants Lys2Ala, Leu6Ala, and Arg13Ala were purified for comparing their bioactivity against wild-type mutacin 1140. Mutants Leu6Ala and Arg13Ala were two-fold more active against the indicator bacterium Micrococcus luteus (Table 10). These mutants prove to be beneficial in optimization of the antibacterial compound for the treatment of infectious diseases. These mutants also provide greater stability to the compound. For example, the Arg13Ala mutation makes the molecule less sensitive to gastric proteases.

The Lys2Ala mutant only had greater activity in the overlay assay, which suggests that this mutation leads to an increase in production of the compound. This mutant would be useful for using the bacterium or engineered bacterium as a probiotic.

TABLE 10 Minimum inhibitory activity of mutant mutacin 1140 against indicator strain Micrococcus luteus. Antibiotic MIC (μg/ml) Wild-type mutacin 1140 0.125 Mutant Lys2Ala 0.125 Mutant Leu6Ala 0.0625 Mutant Arg13Ala 0.0625

SEQ ID NO: 1 MKNSAAREAFKGANHPAGMVSEEELKALVGGNDVNPETTPATTSSWTCITA GVTVSASLCPTTKCTSRC SEQ ID NO: 2 MKTEKKVLDELSLHASAKMGARDVESSMNADSTPVLASVAVSMELLPTASV LYSDVAGCFKYSAKHHC SEQ ID NO: 3 MKNSKDILNNAIEEVSEKELMEVAGGKRGSGWIATITDDCPNSVFVCC SEQ ID NO: 4 MNKLNSNAVVSLNEVSDSELDTILGGNRWWQGVVPTVSYECRMNSWQHVFT CC SEQ ID NO: 5 MKEKNMKKNDTIELQLGKYLEDDMIELAEGDESHGGTTPATPAISILSAYI STNTCPTTKCTRAC SEQ ID NO: 6 MSALAIEKSWKDVDLRDGATSHPAGLGFGELTFEDLREDRTIYAASSGWVC TLTIECGTVICAC SEQ ID NO: 7 MSQEAIIRSWKDPFSRENSTQNPAGNPFSELKEAQMDKLVGAGDMEAACTF TLPGGGGVCTLTSECIC SEQ ID NO: 8 MEAVKEKNDLFNLDVKVNAKESNDSGAEPRIASKFICTPGCAKTGSFNSYC C SEQ ID NO: 9 MEAVKEKNELFDLDVKVNAKESNDSGAEPRIASKFLCTPGCAKTGSFNSYC C SEQ ID NO: 10 MSNTQLLEVLGTETFDVQENLFTFDTTDTIVAESNDDPDTRFKSWSFCTPG CAKTGSFNSYCC SEQ ID NO: 11 MSNTQLLEVLGTETFDVQEDLFAFDTTDTTIVASNDDPDTRFKSWSLCTPG CARTGSFNSYCC SEQ ID NO: 12 MRNDVLTLTNPMEEKELEQILGGGNGVLKTISHECNMNTWQFLFTCC SEQ ID NO: 13 MPADILETRTSETEDLLDLDLSIGVEEITAGPAVTSWSLCTPGCTSPGGGS NCSFCC SEQ ID NO: 14 TTPATTSSWTCITAGVTVSASLCPTTKCTSRC SEQ ID NO: 15 STPVLASVAVSMELLPTASVLYSDVAGCFKYSAKHHC SEQ ID NO: 16 KRGSGWIATITDDCPNSVFVCC SEQ ID NO: 17 NRWWQGVVPTVSYECRMNSWQHVFTCC SEQ ID NO: 18 TTPATPAISILSAYISTNTCPTTKCTRAC SEQ ID NO: 19 SSGWVCTLTIECGTVICAC SEQ ID NO: 20 CTFTLPGGGGVCTLTSECIC SEQ ID NO: 21 IASKFICTPGCAKTGSFNSYCC SEQ ID NO: 22 IASKFLCTPGCAKTGSFNSYCC SEQ ID NO: 23 FKSWSFCTPGCAKTGSFNSYCC SEQ ID NO: 24 FKSWSLCTPGCARTGSFNSYCC SEQ ID NO: 25 GNGVLKTISHECNMNTWQFLFTCC SEQ ID NO: 26 VTSWSLCTPGCTSPGGGSNCSFCC

Example 6—Core Peptide Mutants of Mutacin 1140 and its Effect on Bactericidal Activity

Mutacin 1140 has demonstrated activity against several resistant strains of S. pneumoniae. Core peptide mutants of mutacin 1140 that have improved stability, superior pharmacokinetics, and higher activity against S. pneumoniae are provided. Particularly, core peptide mutant R13A of mutacin 1140 is provided as an alternative treatment option for an S. pneumoniae infection.

The formulations of the core peptide mutants, particularly, formulations suitable for intravenous administration, are also disclosed. Such formulations have improved toxicity profile and ability to treat an S. pneumoniae infection. Toxicological and pharmacokinetic evaluation of R13A core mutant of mutacin 1140 following intravenous route of administration are described. R13A core mutant of mutacin 1140 effectively treats a respiratory infection and bacteremia caused by S. pneumoniae.

The disruption of normal upper respiratory flora caused as a result of conventional antibiotic treatment is the basis for the rampant spread of S. pneumoniae. Conjugate vaccines protect against select serotypes, but the niches occupied by these are being filled by one of the other 92 serotypes of S. pneumoniae. The use of broad spectrum antibiotics actually increases the spread of antibiotic resistant S. pneumoniae infections in hospitals. Furthermore, the overuse of conventional antibiotics has led to an emergence of resistant organisms by creating reservoirs of resistant bacteria within the nasal passages that confer the resistance to S. pneumoniae. There are more than 4 million S. pneumoniae infections each year. Pneumococcal ear infections (otitis media) make up 1.5 million of these cases, and they are a direct result of conventional antibiotic use (CDC, Antibiotic Resistance Report 2013). At least 400,000 hospitalizations are estimated from pneumococcal pneumonia each year in the United States (CDC). Approximately thirty percent of S. pneumoniae infections are resistant to one or more antibiotics. These infections lead to excessive hospital stays and death. Patients with pneumococcal pneumonia have a high incidence of bacteremia (˜30%) leading to death in about 6% of the cases. Despite the positive outcome of the conjugate vaccine, a need exists for developing alternative approaches to lessen the burden associated with pneumococcal pneumonia. The increasing tolerance of pneumococcal infections to penicillin and vancomycin is alarming. Certain embodiments of the invention provide new antibiotics with potent activity against S. pneumoniae that can be added to the dwindling arsenal of treatment options.

Mutacin is a peptide belonging to class I lantibiotics and is naturally produced by a strain of the common oral bacterium, Streptococcus mutans. This compound has demonstrated activity against several Gram-positive pathogens, including oxacillin- and vancomycin-resistant Staphylococcus aureus and vancomycin-resistant E. faecalis. The post-translational incorporation of lanthionine rings confers proteolytic stability, which should enhance its stability and use in animals. However, mutacin 1140 like other lantibiotics has a short half-life in animals. The invention provides core peptide mutants of mutacin 1140 that have potent activity against S. pneumoniae and have the pharmacokinetic and pharmacodynamic parameters supporting its potential usefulness in treating a pneumococcal infection in animals.

Mode of action of mutacin: Sequential subculturing of S. aureus and S. pneumoniae in sub-inhibitory concentrations of mutacin resulted in only a three-fold increase in the minimum inhibitory concentration, suggesting that this antibiotic is a good candidate as a therapeutic agent against infection. Mutacin functions, much like vancomycin, by binding to lipid II, which is essential for cell-wall formation. Although vancomycin shares the same target, it uses a different mechanism to inhibit cell wall synthesis. Vancomycin binds to a different region on lipid II, which are the terminal D-Ala-D-Ala residues of the peptide. This difference in activity possibly contributes to mutacin's impressive ability to kill vancomycin-resistant strains of bacteria. Mutacin kills bacteria by sequestering the essential cell wall biosynthetic molecule lipid II into domains away from the sites that are required for cell wall synthesis. Lipid II is essential for the transport of cell wall subunits across the bacterial cytoplasmic membrane. This highly dynamic molecule is present in all eubacteria in relatively small amounts. Lipid II is assembled on the cytoplasmic side of the bacterial membrane and carries one complete peptidoglycan subunit (GlcNAc-MurNAc-pentapeptide) across the plasma membrane. A novel lipid II-binding motif for mutacin-related lantibiotics has been characterized by NMR, in which the N-terminal portion of the lantibiotic, lanthionine rings A and B, interact with the pyrophosphate, peptidoglycan MurNAc, and first isoprene of lipid II. Mutacin activity is also attributed to bacterial membrane disruption. No protein receptor is required for the bactericidal activity of this class of antibiotics, and therefore, it cannot easily be overcome via genetic adaptation. This unique mechanism of action for mutacin and similar lantibiotics support the long-term value of a new antibiotic.

Therapeutic activity of mutacin: The solubility of pure native mutacin in aqueous saline solution exceeds 0.5 mg/mL, which is well above its low inhibitory concentration against Gram-positive bacteria. Mutacin has a broad spectrum of activity against Gram-positive bacteria. In particular, mutacin has a submicromolar activity against S. pneumoniae. Furthermore, mutacin has been shown to be active against oxacillin- and vancomycin-resistant S. aureus, as well as vancomycin-resistant E. faecalis. No activity was observed against Gram-negative bacteria or yeast consistent with previous lantibiotic studies. The level of activity varied by more than 128-fold between species of Gram-positive bacteria, which may promote its use for treating S. pneumoniae infections. Disease associated with S. pneumoniae is usually attributed to the disruption of host flora. The lack of activity against Gram-negative bacteria and the increased susceptibility of pneumococcal bacteria relative to other Gram-positive bacteria may promote the reestablishment of the host's protective flora during treatment. Results of acute toxicity studies in rodents support the further development of analogs of mutacin for the treatment of Gram-positive infections. Mouse and rat models were tested by bolus intravenous injection of mutacin in normal saline. Both models readily tolerated doses up to 25 mg/kg body weight. Time-kill studies have been performed by using strains of medically important Gram-positive species, S. aureus and E. faecalis. The results of time-kill investigations showed that mutacin exhibited a rapid initial killing against multidrug resistant S. aureus, whereas bacteriostatic activity was observed against a vancomycin resistant strain of E. faecalis. This is very similar to the activity seen with vancomycin. However, the native mutacin 1140 has a short half-life and is rapidly cleared from the blood, which prevents its use and development as an effective treatment option.

Several mutacin core peptide mutants were tested for their ability to inhibit several clinical strains of S. pneumoniae, while also having superior pharmacokinetic and stability properties. The pharmacokinetics and efficacy of certain mutacin core peptide mutants were tested to provide treatment options for an S. pneumoniae infection.

Example 7—Formulation, Toxicological, and Pharmacokinetic Evaluation of the R13A Core Peptide Mutant of Mutacin 1140 Following Intravenous Administration

R13A core peptide mutant of mutacin 1140 was tested as a novel therapeutic for pneumococcal infections. As described above, native mutacin has several attributes to serve as a successful therapeutic agent, but its low peak plasma concentration and rapid clearance from blood prevents its development as an effective therapy. Core peptide mutants of mutacin 1140 that have superior properties compared to native mutacin are provided. Also, formulations of R13A that improves pharmacokinetic properties of R13A are also provided.

FIG. 11 illustrates the bioactivity of various core peptide mutants of mutacin 1130. The activity of the core mutant peptides is expressed as a ratio of the area of the zone of inhibition of each mutant strain to the area of the zone of inhibition of the wild-type strain against indicator strain of Micrococcus luteus. A value of one denotes similar activity to wild-type, but values greater than one shows higher activity for the mutants. The deferred antagonism assay is an overlay assay of the indicator strain onto plates containing heat killed colonies of the mutacin producer strain after growing overnight. Core peptide mutants having inhibitory activity were isolated and the purified products were further evaluated by a standard minimum inhibitory concentration (MIC) assay. MICs for some of the core peptide mutants of mutacin 1140 are provided in Table 11.

TABLE 11 Bioactivity of core peptide mutants of mutacin 1140. C. accolens KPL 1818 and C. accolens ATCC 49725 were cultured in THyex broth supplemented with 1% Tween 80 to promote the bacterial growth. MICs of wild-type mutacin 1140 were done against M. luteus. S. aureus, and S. pneumoniae with or without 1% Tween 80 at the same time and there was no difference in activities. MICs and MCLs are presented in micrograms per milliliter. M. luteus S. aureus C. accolens C. accolens S. pneumonia Mutacin 1140 ATCC 10240 ATCC 25923 ATCC 49725 KPL 1818 ATCC 27336 Analogs MIC MLC MIC MLC MIC MLC MIC MLC MIC MLC Wild-Type 0.0625 0.0625 8 8 0.125 0.125 1 2 0.5 0.5 Mutacin Mutations within ring A S5T 4 4 >32 >32 >4 >4 >4 >4 2 2 S5G 0.125 0.125 8 8 0.5 0.5 0.5 0.5 0.0078 0.0078 Mutations within hinge region R13A 0.0625 0.0625 16 16 0.25 0.5 1 1 0.125 0.125 T14G 0.0625 0.0625 >32 >32 0.0625 0.0625 0.25 0.5 0.5 0.5 T14A 0.125 0.125 8 16 0.25 0.25 0.5 2 0.5 0.5 G15A* 0.125 0.125 16 16 1 1 1 2 0.5 0.5 R13A:T14A 0.25 0.5 32 32 0.5 0.5 0.5 0.5 2 2 A12T:T14G 0.25 0.25 >32 >32 0.125 0.25 0.5 1 2 2 Mutations within both ring A and hinge region S5G:T14A 0.125 0.125 >32 >32 4 4 — — 4 4 S5A:T14G 0.0625 0.125 32 32 0.25 0.25 0.5 1 0.25 0.25 S5G:T14G 0.5 0.5 8 16 1 1 0.5 1 2 2 S5A:A12S 0.125 0.25 16 32 0.25 0.25 0.5 1 0.125 0.125 dehydrated S5A:A12S 0.125 0.25 16 16 — — — — 0.125 0.125 undehydrated S5A:R13S 0.125 0.25 >32 >32 2 2 2 4 0.5 0.5 S5G:R13A:T14A 2 16 >32 >32 >4 >4 >4 >4 8 >16

Selective activity and stability of analogs: Several core peptide mutants are provided that have improved activity against our ATCC strain of S. pneumoniae. These core peptide mutants were also selected based on the absence of a dehydrated residue Dha/Dhb or the proteolytically susceptible arginine residue. While the S5G, S5A:T14G, S5A, T14A, and T14G had low micromolar activity against one or more of the clinical S. pneumoniae isolates, the R13A analog had superior activity against most strains compared to wild-type mutacin (Table 12). Although the analog S5G had improved activity against S. pneumoniae ATCC 27336 compared to native mutacin and R13A, the S5G had less activity against all other tested strains of S. pneumoniae. Further supporting data for the development of the R13A analog are: 1) the activity of R13A was unchanged when tested in the presence of 50% serum, 2) In a trypsin stability screen (native mutacin and the analogs were spotted on a THyex plate overlayed with M. luteus before and after treatment with 0.5 mg/mL of trypsin at 37° C. for 30 minutes), R13A has improved stability compared to native mutacin, T14A, and S5A:T14G (FIG. 13) The solubility of the R13A analog in saline is greater than 2 mg/mL, which is a four-fold increase in solubility of native mutacin. 4) The R13A mutation prevents feedback inhibition of mutacin 1140 production, leading to a 100% increase in yield from the culture liquor. The improved stability of R13A in the presence of trypsin protease is encouraging when compared to native mutacin, since trypsin-like proteases are abundantly present in the blood. They are important for immunoregulation and blood coagulation. The observed increase in stability of the R13A analog will likely be advantageous in an animal model.

TABLE 12 MICs of mutacin analogs against clinical S. pneumoniae isolates. S. pneumoniae isolates required the addition of 50% blood for growth in the bioassay. MICs and MLCs are presented in micrograms per milliliter. S. pneu- S. pneu- S. pneu- S. pneu- S. pneu- moniae moniae moniae moniae moniae AI8 AI11 AI14 AI16 AI17 Mutacin 1140 1 1 0.125 1 0.25 R13A 0.5 0.5 0.25 0.5 0.25 S5G >8 8 >8 >8 2 S5A:T14G >8 >8 >8 >8 8 S5A 8 4 >8 4 4 T14A 8 4 2 8 8 T14G 8 2 1 8 8

Pharmacokinetic comparison of native mutacin and analogs: Murine models of S. pneumoniae infection are easy to use and commonly employed to study efficacy of antibiotic treatments. Murine models of S. pneumoniae infection provide an easy and reliable platform to test the efficacy of candidate drugs for treatment. The efficacy of the novel formulation of R13A was evaluated in a mouse model of pneumococcal pneumonia.

The compounds were dissolved in normal saline for all pharmacokinetic studies. An extraction protocol was developed in vitro by the addition of each compound to commercially bought BALB/c mouse serum. The compounds were extracted by the addition of 70% ACN containing 0.1% TFA/30% methanol containing 0.4% formic acid. The extract was then analyzed by LC-MS using a TSQ Vantage Triple Quad mass spectrometer. A standard curve was generated for each compound using known dilutions of the compounds in serum, which was then extracted. The R-squared values for each standard exceeded 0.98. BALB/c mice were used to evaluate pharmacokinetics of the compounds in vivo. A 2.5 mg/kg i. v. dose was evaluated for native mutacin, R13A, SSG, and double mutant S5A:T14G (FIG. 12A). A polynomial second order was used to estimate the peak plasma concentration and half-life of the R13A. The peak plasma concentration of R13A was 1700 ng/mL and the estimated half-life was 70 minutes. At 70 minutes, native mutacin and other mutant analogs were about to be cleared from the blood. Interestingly, the double mutant S5A:T14G performed the worst. This data in combination with the SSG data, suggests that the Dhb residue normally at position 14 is important for peptide stability. Possibly, the Dhb14 residue may protect the peptide from trypsin-like proteases in the blood. As seen in the in vitro studies, at 125 ng/mL, the R13A analog reduces the number of S. pneumonia by 2-logs (FIG. 12B). Thus, taking the dynamics of cell death into account and the pharmacokinetics of the R13A, the R13A in serum is above the inhibitory concentration for S. pneumonia long enough to kill the pathogen. R13A is more stable and more active against S. pneumoniae strains and is pharmacokinetically superior to native mutacin.

Example 8—Formulations of Antimicrobial Peptides

Antimicrobial peptides can have poor solubility. Solubilizing/surfactant agents are used to meet the strict USP requirements for purity and clarity of injectable formulations. R13A is soluble at 2 mg/ml in saline solution. To further improve the solubility, solubilizing agents can be used. The solid stock of R13A can be prepared by lyophilization, stored at 4° C., and reconstituted as needed. In certain embodiments, the formulation comprises 50 mg of R13A, 50 mg of fructose (stabilizer), 269 mg of mannitol (bulking agent), 125 mg of polysorbate-80 (solubilizing agent), and 6 mg of tartaric acid (buffer). 50 mg of solid stock can be reconstituted in 1-2 mL of water as needed (a 16-8 mg/mL of active agent stock). In further embodiments, the formulations of R13A further comprise excipients such as β-cyclodextrins, Tween 20, PEG 400, demethylacetamide. Such formulations can contain up to 8 mg/mL R13A. Also, 5-20% ethanol can be used to reconstitute the solid stock.

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims. In addition, any elements or limitations of any invention or embodiment thereof disclosed herein can be combined with any and/or all other elements or limitations (individually or in any combination) or any other invention or embodiment thereof disclosed herein, and all such combinations are contemplated within the scope of the invention without limitation thereto.

REFERENCES

-   1. Guillemot D, Varon E, Bernède C, Weber P, Henriet L, Simon S,     Laurent C, Lecoeur H, Carbon C. 2005. Reduction of antibiotic use in     the community reduces the rate of colonization with penicillin     G-nonsusceptible Streptococcus pneumoniae. Clin Infect Diseases     41:930-938. -   2. Allgaier, H.; Jung, G.; Werner, R. G.; Schneider, U.; Zahner, H.     Angew. Chem.-Int. Edit. Engl. 1985, 24, 1051-1053. -   3. Bierbaum G, Sahl H G. 2009. Lantibiotics: mode of action,     biosynthesis and bioengineering. Curr Pharm Biotechnol 10:2-18. -   4. Bierbaum, G.; Sahl, H. G. Curr. Pharm. Biotechnol. 2009, 10,     2-18. -   5. Birri, D. J., D. A. Brede, and I. F. Nes, Salivaricin D, a novel     intrinsically trypsin-resistant lantibiotic from Streptococcus     salivarius 5M6c isolated from a healthy infant. Applied And     Environmental Microbiology, 2012. 78(2): p. 402-410. -   6. Blaesse, M.; Kupke, T.; Huber, R.; Steinbacher, S. 2003, 59,     1414-1421. -   7. Blaesse, M.; Kupke, T.; Huber, R.; Steinbacher, S. Embo J. 2000,     19, 6299-6310. -   8. Boakes, S.; Cortes, J.; Appleyard, A. N.; Rudd, B. A. M.;     Dawson, M. J. Mol. Microbiol. 2009, 72, 1126-1136. -   9. Bomar, L., et al., Corynebacterium accolens Releases     Antipneumococcal Free Fatty Acids from Human Nostril and Skin     Surface Triacylglycerols. Mbio, 2016. 7(1): p. e01725-e01715. -   10. Bonelli, R. R.; Schneider, T.; Sahl, H. G.; Wiedemann, I.     Antimicrob Agents Chemother 2006, 50, 1449-57. -   11. Breukink, E.; Wiedemann, I.; van Kraaij, C.; Kuipers, O. P.;     Sahl, H. G.; de Kruijff, B., Use of the cell wall precursor lipid II     by a pore-forming peptide antibiotic. Science 1999, 286, 2361-2364. -   12. Carrillo, A. K.; VanNieuwenhze, M. S. Org. Lett. 2012, 14,     1034-1037. -   13. Chatterjee C, Paul M, Xie L, van der Donk W A. 2005.     Biosynthesis and mode of action of lantibiotics. Chem Rev     105:633-684. -   14. Chen S, Wilson-Stanford S, Cromwell W, Hillman J D, Guerrero A,     Allen C A, Sorg J A, Smith L. 2013. Site-directed mutations in the     lanthipeptide mutacin 1140. Appl Environ Microbiol 79:4015-4023. -   15. Chiavolini, D., G. Pozzi, and S. Ricci, Animal Models of     Streptococcus pneumoniae Disease. Clinical Microbiology     Reviews, 2008. 21(4): p. 666-685. -   16. Claesen, J.; Bibb, M. Proc. Natl. Acad. Sci. U.S.A. 2010, 107,     16297-16302. -   17. Craik, D. J.; Fairlie, D. P.; Liras, S.; Price, D. Chem. Biol.     Drug Des. 2013, 81, 136-147. -   18. Crowther, G. S.; Baines, S. D.; Todhunter, S. L.; Freeman, J.;     Chilton, C. H.; Wilcox,

M. H. J. Antimicrob. Chemother. 2013, 68, 168-176.

-   19. Dischinger, J.; Chipalu, S. B.; Bierbaum, G. Int. J. Med.     Microbiol. 2014, 304, 51-62. -   20. Eaton, D. L. and C. D. Klaassen, Principles of Toxicology.     Casarett and Doull's Toxicology, ed. C.D. In: Klaassen. 1996:     McGraw-Hill, New York. -   21. Escano J, Smith L. 2015. Multipronged approach for engineering     novel peptide analogues of existing lantibiotics. Expert Opin Drug     Discov. 10:857-70. -   22. Escano J, Stauffer B, Brennan J, Bullock M, Smith L. 2014. The     leader peptide of mutacin 1140 has distinct structural components     compared to related class I lantibiotics. Microbiol Open 3:961-972. -   23. Escano J, Stauffer B, Brennan J, Bullock M, Smith L. 2015.     Biosynthesis and transport of the lantibiotic mutacin 1140 produced     by Streptococcus mutans. J Bacteriology 197:1173-1184. -   24. Escano, J. and L. Smith, Multipronged approach for engineering     novel peptide analogues of existing lantibiotics. Expert Opinion On     Drug Discovery, 2015. Posted online on May 23, 2015. -   25. Escano, J., et al., Biosynthesis and transport of the     lantibiotic mutacin 1140 produced by Streptococcus mutans. Journal     Of Bacteriology, 2015. 197(7): p. 1173-1184. -   26. Foulston, L. C.; Bibb, M. J. Proc. Natl. Acad. Sci. U.S.A. 2010,     107, 13461-13466. -   27. Foulston, L.; Bibb, M., Feed-Forward Regulation of     Microbisporicin Biosynthesis in Microbispora corallina. J.     Bacteriol. 2011, 193, 3064-3071. -   28. Garcia-Reynaga, P.; Carrillo, A. K.; VanNieuwenhze, M. S. Org.     Lett. 2012, 14, 1030-1033. -   29. Ghobrial O, Derendorf H, Hillman J D. 2010. Human serum binding     and its effect on the pharmacodynamics of the lantibiotic MU1140.     Europ J Pharma Sci 41:658-664. -   30. Ghobrial O, Derendorf H, Hillman J D. 2010. Pharmacokinetic and     pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci     99:2521-2528. -   31. Ghobrial O G, Derendorf H, Hillman J D. 2009. Pharmacodynamic     activity of the lantibiotic MU1140. Int J Antimicrob Agents     33:70-74. -   32. Ghobrial, O.; Derendorf, H.; Hillman, J. D. J. Pharm. Sci. 2010,     99, 2521-2528. -   33. Goldman, R. C.; Baizman, E. R.; Longley, C. B.; Branstrom, A. A.     FEMS Microbiol. Lett. 2000, 183, 209-214. -   34. Goldsmith C E, Hara Y, Sato T, Nakajima T, Nakanishi S, Mason C,     Moore J E, Matsuda M, Coulter W A. 2015. Comparison of antibiotic     susceptibility in viridans group streptococci in low and high     antibiotic-prescribing General Practices. J Clin Pharm Therap     40:204-207. -   35. Guillemot, D., et al., Reduction of antibiotic use in the     community reduces the rate of colonization with penicillin     G-nonsusceptible Streptococcus pneumoniae. Clinical Infectious     Diseases: An Official Publication Of The Infectious Diseases Society     Of America, 2005. 41(7): p. 930-938. -   36. Hart, P.; Oppedijk, S. F.; Breukink, E.; Martin, N. I.     Biochemistry 2016, 55, 232-237. -   37. Hasper H E, Kramer N E, Smith J L, Hillman J D, Zachariah C,     Kuipers O P, de Kruijff B, Breukink E. 2006. An alternative     bactericidal mechanism of action for lantibiotic peptides that     target lipid II. Science 313:1636-1637. -   38. Hasper, H. E.; de Kruijff, B.; Breukink, E. Biochemistry 2004,     43, 11567-11575. -   39. Hathaway L J, Brugger S D, Morand B, Bangert M, Rotzetter J U,     Hauser C, Graber W A, Gore S, Kadioglu A, Mühlemann K. 2012. Capsule     type of Streptococcus pneumoniae determines growth phenotype. Plos     Pathogens 8:e1002574-e1002574. -   40. Hau, I., et al., Impact of pneumococcal conjugate vaccines on     microbial epidemiology and clinical outcomes of acute otitis media.     Paediatric Drugs, 2014. 16(1): p. 1-12. -   41. Hayakawa, Y.; Sasaki, K.; Nagai, K.; Shin-ya, K.;     Furihata, K. J. Antibiot. 2006, 59, 6-10. -   42. Hillman J D, Novak J, Sagura E, Gutierrez J A, Brooks T A,     Crowley P J, Hess M, Azizi A, Leung K P, Cvitkovitch D, Bleiweis     A S. 1998. Genetic and biochemical analysis of mutacin 1140, a     lantibiotic from Streptococcus mutans. Infect Immun 66:2743-2749. -   43. Hillman, J. D. Antonie Van Leeuwenhoek 2002, 82, 361-366. -   44. Hsu, S. T. D.; Breukink, E.; Tischenko, E.; Lutters, M. A. G.;     de Kruijff, B.; Kaptein, R.; Bonvin, A.; van Nuland, N. A. J. Nat.     Struct. Mol. Biol. 2004, 11, 963-967. -   45. Hughes, J.; Smith, T. W.; Kosterlitz, H. W.; Fothergill, L. A.;     Morgan, B. A.; Morris, H. R. Nature 1975, 258, 577-579. -   46. Islam, M. R.; Nishie, M.; Nagao, J.; Zendo, T.; Keller, S.;     Nakayama, J.; Kohda, D.; Sahl, H. G.; Sonomoto, K. J Am Chem Soc     2012, 134, 3687-90. -   47. Joshi, P. R.; McGuire, J.; Neff, J. A. J. Biomed. Mater. Res.     Part B 2009, 91B, 128-134. -   48. Kaur, R., et al., Correlation of nasopharyngeal cultures prior     to and at onset of acute otitis media with middle ear fluid     cultures. BMC Infectious Diseases, 2014. 14: p. 640-640. -   49. Kellner, R.; Jung, G.; Horner, T.; Zahner, H.; Schnell, N.;     Entian, K. D.; Gotz, F. Eur. J. Biochem. 1988, 177, 53-59. -   50. Konno M, Baba S, Mikawa H, Hara K, Matsumoto F, Kaga K,     Nishimura T, Kobayashi T, Furuya N, Moriyama H, Okamoto Y, Furukawa     M, Yamanaka N, Matsushima T, Yoshizawa Y, Kohno S, Kobayashi K,     Morikawa A, Koizumi S, Sunakawa K, Inoue M, Ubukata K. 2006. Study     of upper respiratory tract bacterial flora: first report. Variations     in upper respiratory tract bacterial flora in patients with acute     upper respiratory tract infection and healthy subjects and     variations by subject age. J Infect Chemother 12:83-96. -   51. Konno, M., et al., Study of nasopharyngeal bacterial flora.     Variations in nasopharyngeal bacterial flora in schoolchildren and     adults when administered antimicrobial agents. Journal Of Infection     And Chemotherapy: Official Journal Of The Japan Society Of     Chemotherapy, 2007. 13(4): p. 235-254. -   52. Kupke, T.; Gotz, F. FEMS Microbiol. Lett. 1997, 153, 25-32. -   53. Kupke, T.; Kempter, C.; Gnau, V.; Jung, G.; Gotz, F. J. Biol.     Chem. 1994, 269, 5653-5659. -   54. Kupke, T.; Kempter, C.; Jung, G.; Gotz, F. J. Biol. Chem. 1995,     270, 11282-11289. -   55. Lepak, A. J., et al., In vivo pharmacokinetics and     pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine     thigh infection model. Antimicrobial Agents And Chemotherapy, 2015.     59(2): p. 1258-1264. -   56. Levengood, M. R.; Knerr, P. J.; Oman, T. J.; van der     Donk, W. A. J. Am. Chem. Soc. 2009, 131, 12024-12025. -   57. Li, Y.-H.; Tang, N.; Aspiras, M. B.; Lau, P. C. Y.; Lee, J. H.;     Ellen, R. P.; Cvitkovitch, D. G. J. Bacteriol. 2002, 184, 2699-2708. -   58. Lubelski, J.; Khusainov, R.; Kuipers, O. P. J Biol Chem 2009,     284, 25962-72. -   59. Maher, S.; Vilk, G.; Kelleher, F.; Lajoie, G.; McClean, S.     Int. J. Pept. Res. Ther. 2009, 15, 219-226. -   60. Meyer, H. E.; Heber, M.; Eisermann, B.; Korte, H.; Metzger, J.     W.; Jung, G. Anal. Biochem. 1994, 223, 185-190. -   61. Moine, P., et al., In vivo efficacy of a broad-spectrum     cephalosporin, ceftriaxone, against penicillin-susceptible and     -resistant strains of Streptococcus pneumoniae in a mouse pneumonia     model. Antimicrobial Agents and Chemotherapy, 1994. 38(9): p.     1953-1958. -   62. Mota-Meira, M., H. Morency, and M. C. Lavoie, In vivo activity     of mutacin B-Ny266. The Journal Of Antimicrobial Chemotherapy, 2005.     56(5): p. 869-871. -   63. Mutagenesis of Lysine 12 Leads to the Identification of     Derivatives of Nisin A with Enhanced Antimicrobial Activity. Plos     One 2013, 8, e58530. -   64. Novak, R., et al., Penicillin tolerance genes of Streptococcus     pneumoniae: The ABC-type manganese complex Psa. Mol.     Microbiol., 1998. 29: p. 1285-1296. -   65. Okesli, A.; Cooper, L. E.; Fogle, E. J.; van der Donk, W. A. J.     Am. Chem. Soc. 2011, 133, 13753-13760. -   66. Olivares A, T. J., Arellano-Galindo J, Zuñiga G, Escalona G,     Vigueras J C, Marin P, Xicohtencatl J, Valencia P,     Velázquez-Guadarram N. 2011. pep27 and lytA in Vancomycin-Tolerant     Pneumococci. J Microbiol Biotechnol. 21:1345-51. -   67. Ortega, M. A.; Hao, Y.; Zhang, Q.; Walker, M. C.; van der     Donk, W. A.; Nair, S. K. Nature 2015, 517, 509-512. -   68. Paiva, A. D.; Breukink, E.; Mantovani, H. C. Antimicrob Agents     Chemother 2011, 55, 5284-93. -   69. Pettigrew, M. M., et al., Upper respiratory tract microbial     communities, acute otitis media pathogens, and antibiotic use in     healthy and sick children. Applied And Environmental     Microbiology, 2012. 78(17): p. 6262-6270. -   70. Qi, F. X.; Chen, P.; Caufield, P. W. Appl. Environ. Microbiol.     1999, 65, 652-658. -   71. Ross, A. C.; Liu, H. Q.; Pattabiraman, V. R.; Vederas, J. C. J.     Am. Chem. Soc. 2010, 132, 462-463. -   72. Scherer, K. M.; Spille, J. H.; Sahl, H. G.; Grein, F.;     Kubitscheck, U. Biophys. J. 2015, 108, 1114-1124. -   73. Shi, Y. X.; Bueno, A.; van der Donk, W. A. Chem. Commun. 2012,     48 (89), 10966-10968. -   74. Silhavy, T. J., D. Kahne, and S. Walker, The bacterial cell     envelope. Cold Spring Harbor Perspectives In Biology, 2010. 2(5): p.     a000414-a000414. -   75. Sit, C. S.; Yoganathan, S.; Vederas, J. C. Accounts Chem. Res.     2011, 44, 261-268. -   76. Smith L, Hasper H, Breukink E, Novak J, Cerkasov J, Hillman J D,     Wilson-Stanford S, Orugunty R S. 2008. Elucidation of the     Antimicrobial Mechanism of Mutacin 1140. Biochemistry. 47:3308-14. -   77. Smith L, Novak J, Rocca J, McClung S, Hillman J D, Edison     A S. 2000. Covalent structure of mutacin 1140 and a novel method for     the rapid identification of lantibiotics. Eur J Biochem     267:6810-6816. -   78. Smith, L. and J. D. Hillman, Therapeutic potential of type A (I)     lantibiotics, a group of cationic peptide antibiotics. Current     Opinion In Microbiology, 2008. 11(5): p. 401-408. -   79. Smith, L., et al., Elucidation of the Antimicrobial Mechanism of     Mutacin 1140. Biochemistry, 2008: p. accepted. -   80. Smith, L.; Zachariah, C.; Thirumoorthy, R.; Rocca, J.; Novak,     J.; Hillman, J. D.; Edison, A. S. Biochemistry 2003, 42,     10372-10384. -   81. Steinhoff, M. C., Animal models for protein pneumococcal vaccine     evaluation: A summary. Vaccine. 25(13): p. 2465-2470. -   82. Strauss, E.; Zhai, H.; Brand, L. A.; McLafferty, F. W.;     Begley, T. P. Biochemistry 2004, 43, 15520-15533. -   83. Stubbendieck, R. M.; Straight, P. D. PLoS genetics 2015, 11,     e1005722. -   84. Suda, S.; Lawton, E. M.; Wistuba, D.; Cotter, P. D.; Hill, C.;     Ross, R. P. J. Bacteriol. 2012, 194, 708-714. -   85. Tabor, A. B. Bioorganic Chem. 2014, 55, 39-50. -   86. Turner, R. D., et al., Peptidoglycan architecture can specify     division planes in Staphylococcus aureus. Nature     Communications, 2010. 1: p. 26-26. -   87. van Heel, A. J., M. Montalban-Lopez, and O. P. Kuipers,     Evaluating the feasibility of lantibiotics as an alternative therapy     against bacterial infections in humans. Expert Opinion On Drug     Metabolism & Toxicology, 2011. 7(6): p. 675-680. -   88. van Heijenoort, J., Formation of the glycan chains in the     synthesis of bacterial peptidoglycan. Glycobiology, 2001. 11(3): p.     25R-36R. -   89. Velasquez, J. E.; Zhang, X. G.; van der Donk, W. A. Chem. Biol.     2011, 18, 857-867. -   90. Vouillamoza J, Entenza J, Giddey M, Fischetti V, Moreillon P,     Resch G. Bactericidal synergism between daptomycin and the phage     lysin Cpl-1 in a mouse model of pneumococcal bacteraemia. 2013.     Inter J Antimicrob Agents 42:416-421. -   91. Wilson-Stanford, S.; Kalli, A.; Hakansson, K.; Kastrantas, J.;     Orugunty, R. S.; Smith, L. Appl. Environ. Microbiol. 2009, 75,     1381-1387. -   92. Xie, Z. J.; Okinaga, T.; Qi, F. X.; Zhang, Z. J.; Merritt, J.     Appl. Environ. Microbiol. 2011, 77, 8025-8033. -   93. Yamada, K., et al., In vivo efficacy of KRP-109, a novel     elastase inhibitor, in a murine model of severe pneumococcal     pneumonia. Pulmonary Pharmacology & Therapeutics, 2011. 24(6): p.     660-665. -   94. Yeaman M R, Yount N Y. 2003. Mechanisms of antimicrobial peptide     action and resistance. Pharmacol Rev 55:27-55. 

We claim:
 1. A method of treating a Gram-positive bacterial infection in a subject by administering to the subject a mutant mutacin 1140 lantibiotic comprising SEQ ID NO: 24 or a pharmaceutical composition comprising said mutant mutacin 1140 lantibiotic and a pharmaceutically acceptable carrier, said mutant mutacin 1140 lantibiotic having an amino acid mutation at position 2 in which the lysine residue is substituted with an alanine.
 2. The method of claim 1, wherein a pharmaceutical composition comprising said mutant mutacin 1140 lantibiotic is administered.
 3. The method of claim 1, wherein said mutant mutacin 1140 lantibiotic is administered.
 4. The method of claim 1, wherein a mutant mutacin 1140 lantibiotic comprising SEQ ID NO: 24 and having an amino acid mutation at position 2 in which the lysine residue is substituted with an alanine is administered in combination with a mutant mutacin 1140 lantibiotic comprising SEQ ID NO: 24 and having an amino acid substitution at position 13 in which the arginine residue is substituted with an alanine.
 5. The method of claim 1, wherein a pharmaceutical composition comprising a mutant mutacin 1140 lantibiotic comprising SEQ ID NO: 24 and having an amino acid mutation at position 2 in which the lysine residue is substituted with an alanine is administered in combination with a mutant mutacin 1140 lantibiotic comprising SEQ ID NO: 24 and having an amino acid substitution at position 13 in which the arginine residue is substituted with an alanine. 